書籍詳細

総論

P.9 掲載の参考文献

• 1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008

• 2) Jaffe ES, Harris NL, Stein H, et al.:World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001

• 3) Harris NL, Jaffe ES, Stein H, et al.:A revised European-American classification of lymphoid neoplasms:a proposal from the international lymphoma study group. Blood 84:1361-1392, 1994

• 4) Willemze R, Kerl H, Sterry W, et al.:EORTC classification for primary cutaneous lymphomas:a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997

• 5) Willemze R, Jaffe ES, Burg G, et al.:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
  pubmed

• 6) Oyama T, Ichimura, K, Suzuki R, et al.:Senile EBV+ B-cell lymphoproliferative disorders:a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16-26, 2003
  pubmed

• 7) Shimoyama Y, Yamamoto K, Asano N, et al.:Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders:special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci 99:1085-1091, 2008
  pubmed

• 8) Kimura H, Morishima T, Kanegane H, et al.:Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 187:527-533, 2003
  pubmed

• 9) Ohshima K, Kimura H, Yoshino T, et al.:Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults:overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 58:209-217, 2008

• 10) Savage KJ, Harris NL, Vose JM, et al.:ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008

P.20 掲載の参考文献

• 1) Gorczyca W, Emmons F:Atlas of Differential Diagnosis in Neoplastic, Hematopathology, 2nd ed, Informa Healthcare, UK, 2008

• 2) Kroft SH:Monoclones, monotypes, and neoplasia pittfalls in lymphoma diagnosis. Am J Clin Pathol 121:457-459, 2004

• 3) Rassenti LZ, Huynh L, Toy TL, et al.:ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893-901, 2004
  pubmed

• 4) Wang X, Campoli M, Cho HS, et al.:A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 299:139-151, 2005
  pubmed

• 5) Rossi S, Laurino L, Furlanetto A, et al.:Rabbit monoclonal antibodies:a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 124:295-230, 2005
  pubmed

• 6) Herzenberg LA, Sweet RG, Herzenberg LA:Fluorescence-activated cell sorting. Sci Am 234:108-117, 1976
  pubmed

• 7) Jennings CD, Foon KA:Recent advances in flow cytometry:application to the diagnosis of hematologic malignancy. Blood 90:2863-2892, 1997

• 8) Craig FE, Foon KA:Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111:3941-3967, 2008
  pubmed

• 9) Wilson WH:International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia. Cytometry B Clin Cytom 72(suppl 1):S2, 2007

• 10) Wood B:9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130:680-690, 2006
  pubmed

• 11) Hsi ED, Yegappan S:Lymphoma immunophenotyping:a new era in paraffin-section immunohistochemistry. Adv Anat Pathol 8:218-239, 2001
  pubmed

• 12) Higgins RA, Blankenship JE, Kinney MC:Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med 132:441-461, 2008
  pubmed

• 13) 武田麻衣子, 笠井孝彦, 榎本泰典ほか:自動免疫染色装置による免疫グロブリンL鎖 (IgL) mRNA検出. 第97回日本病理学会総会, 2008年5月15日, 金沢市

• 14) Kaleem Z:Flow cytometric analysis of lymphomas:current status and usefulness. Arch Pathol Lab Med 130:1850-1858, 2006
  pubmed

• 15) 中峯寛和:悪性リンパ腫の病理診断学. 奈良医学雑誌 59:135-148, 2008

• 16) Nakase K, Kita K, Shiku H, et al.:Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms. Am J Clin Pathol 105:761-768, 1996

P.61 掲載の参考文献

• ・外村晶:染色体異常-ヒトの細胞遺伝学. 朝倉書店, 東京, 1978

• ・牧野佐二郎:染色体-人類の細胞遺伝. 医学書院, 東京, 1979

• ・Therman E:Human chromosomes, 2nd ed, Springer-Verlag, New York, 1980

• ・Shaffer LG, Tommerup N:ISCN (2005):An International System for Human Cytogenetic Nomenclature, ed by Shaffer LG, Slovak ML, Campbell LJ, Karger, Basel, 2005

• ・川島康平, 近藤誠 (訳):がん細胞遺伝学のガイドライン, 染色体核型記載の国際規約. An International System for Human Cytogenetic Nomenclature 1991 & 1985, 文光堂, 東京, 1994

• ・臨床染色体診断法, 古庄敏行, 吉田廸弘, 阿部達生ほか編, 古庄敏行監修, 金原出版, 東京, 1996

• ・阿部達生, 稲澤譲治:臨床FISHプロトコール, 秀潤社, 東京, 1997

• ・Barch MJ, Knutsen T, Spurback JL:The AGT cytogenetics laboratory manual, 3rd ed, Lippincott-Raven, USA, 1997

• ・阿部達生, 藤田弘子:新染色体異常アトラス, 南江堂, 東京, 1997

• ・阿部達生, 鎌田七男, 桜井雅温:腫瘍染色体アトラス, 南江堂, 東京, 1986

• ・阿部達生編著:造血器腫瘍アトラス-形態, 免疫, 染色体と遺伝子, 改訂第4版, 日本医事新報社, 東京, 2009

• ・佐藤祐子:血液疾患と染色体異常, 中外医学社, 東京, 1993

• ・横田昇平:分子生物学, 細胞遺伝学, 細胞免疫に基づく血液・固形腫瘍診断マニュアル改訂版, フジメディカル出版, 東京, 2002

• ・血液腫瘍-MIC-M 診断から治療まで-, 谷脇雅史編著, 先端医学社, 東京, 2005

• ・Sandberg AA:The chromosomes in human cancer and leukemia, 2nd ed, Elsevier, New York, 1990

• ・Heim S, Mitelman F:Cancer Cytogenetics, 2nd ed, Wiley-Liss, New York, 1995

• ・Atlas of Genetics and Cytogenetics in Oncology and Haematology (http://atlasgeneticsoncology.org//index.html)

• ・三浦偉久男:染色体検査の出し方と結果の解釈. 臨床血液 48:1393-1399, 2007

• ・三浦偉久男:造血器腫瘍における染色体転座. 臨床血液 49:318-324, 2008

• ・Miura I, Takahashi N, Kobayashi Y, et al.:Molecular cytogenetics of stem cells:Target cells of chromosomal aberrations as revealed by the application of fluorescence in situ hybridization to fluorescence-activated cell sorting. Int Hematol 72:310-317, 2000

• ・Abbas AK, Lichtman AH, Pillai S:Cellular and molecular immunology, 6th ed, Elsevier, Philadelphia, 2007

• ・Murphy K, Travers P, Walport M, et al.:Janeway's immunobiology, 7th ed, Garland Science, New York, 2008

• ・矢田純一:医系免疫学改訂10版, 中外医学社, 東京, 2007

• ・Brown TA:Genomes 3, Garland Science, New York, 2007

P.71 掲載の参考文献

• 1) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
  pubmed

• 2) Noordijk EM, Carde P, Dupouy N, et al.:Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma:long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128-3135, 2006
  pubmed

• 3) Engert A, Schiller P, Josting A, et al.:Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003

• 4) Meyer RM, Gospodarowicz MK, Connors JM, et al.:Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005

• 5) Hasenclever D, Diehl V:A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998

• 6) Solal-Celigny P, Roy P, Colombat P, et al.:Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
  pubmed

• 7) Buske C, Hoster E, Dreyling M, et al.:The Follicular lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504-1508, 2006
  pubmed

• 8) Dave SS, Wright G, Tan B, et al.:Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
  pubmed

• 9) Hoster E, Dreyling M, Klapper W, et al.:A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008
  pubmed

• 10) Shah JJ, Fayad L, Romaguera J:Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 112:2583-2584, 2008

• 11) Gallamini A, Stelitano C, Calvi R, et al.:Peripheral T-cell lymphoma unspecified (PTCL-U):a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004

• 12) Lee J, Suh C, Park YH, et al.:Extranodal natural killer T-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006

• 13) Vose J, Armitage J, Weisenburger D, et al.:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
  pubmed

• 14) Alizadeh AA, Eisen MB, Davis RE, et al.:Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403:503-511, 2000
  pubmed

• 15) Rosenwald A, Wright G, Chan WC, et al.:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
  pubmed

• 16) Hans CP, Weisenburger DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103:275-282, 2004
  pubmed

• 17) Sehn LH, Berry B, Chhanabhai M, et al.:The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109:1857-1861, 2007

• 18) Nyman H, Adde M, Karjalainen-Lindsberg ML, et al.:Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:4930-4935, 2007
  pubmed

• 19) Fu K, Weisenburger DD, Choi WW, et al.:Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 26:4587-4594, 2008
  pubmed

P.72 掲載の参考文献

• i) Niitsu N, Okabe-Kado J, Kasukabe T, et al.:Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 94:3541-3550, 1999
  pubmed

• ii) Niitsu N, Okabe-Kado J, Okamoto M, et al.:Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97:1202-1210, 2001

• iii) Niitsu N, Nakamine H, Okamoto M, et al.:Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma. Clin Cancer Res 10:2482-2490, 2004
  pubmed

P.80 掲載の参考文献

• 1) The Non-Hodgkin's Lymphoma Pathologic Classification Project:National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas:Summary and description of a Working Formulation for clinical usage. Cancer 49:2112-2135, 1982
  pubmed

• 2) Harris NL, Jaffe ES, Stein H, et al.:A revised European-American classification of lymphoid neoplasm:a proposal from the international lymphoma study group. Blood 84:1361-1392, 1994

• 3) World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of Hematopoietic and Lymophoid Tissues, ed by Jaffe ES, Harris NL, Stein H, et al., IARC Press, Lyon, 2001

• 4) WHO Classification of Tumours of Haematopoietic and Lymophoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008

• 5) 岡本昌隆,新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO Classification分類第4版もふまえて-. 日本リンパ網内系雑誌49:86, 2009

• 6) Lymphoma Study Group of Japanese Pathologists:The World Health Organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000

• 7) The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group. Blood 89:3909-3918, 1997

• 8) Hans CP, Weisenberger DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004

P.81 掲載の参考文献

• i) Ackerman AB, Nakano S:Acritique of classifications of lymphoma in historical perspective (and a proposal for how a classification that actually works can be formulated). Am J Dermatopathol 21:288-293, 1999

P.88 掲載の参考文献

• 1) Fisher RI, LeBlanc M, Press OW et al.:New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
  pubmed

• 2) Feugier P, Van Hoof A, Sebban C, et al.:Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005

• 3) Watanabe T, Terui S, Itoh K, et al.:Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci 96:903-910, 2005
  pubmed

• 4) Tobinai K, Watanabe T, Ogura M, et al.:Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100:158-164, 2009
  Medical*Online
  pubmed

• 5) Ogawa Y, Hotta T, Tobinai K, et al.:Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. Ann Oncol 17:330-333, 2006
  pubmed

• 6) Tobinai K, Watanabe T, Ogura M, et al.:Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin lymphoma. J Clin Oncol 24:174-180, 2006
  pubmed

• 7) Stein R, Qu Z, Chen S, et al.:Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10:2868-2878, 2004
  pubmed

• 8) Morshhauser E Leonard JP, Coiffier B, et al.:Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. Proc Am Soc Clin Oncol 24:7530 (abstr), 2006

• 9) Coiffier B, Lepretre S, Pedersen LM, et al.:Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:a phase 1-2 study. Blood 111:1094-1100, 2008
  pubmed

• 10) Hagenbeek A, Gadeberg O, Johnson P, et al.:First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma:results of a phase 1/2 trial. Blood 111:5486-5495, 2008
  pubmed

• 11) Leonard Jp, Coleman M, Ketas JC, et al.:Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21:3051-3059, 2003
  pubmed

• 12) Leonard Jp, Coleman M, Katas JS, et al.:Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma:phase I/II clinical trial results. Clin Cancer Res 10:5327-5334, 2004

• 13) Leonard Jp, Coleman M, Ketas J, et al.:Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23:5044-5051, 2005
  pubmed

• 14) DiJoseph JE Armellino DC, Boghaert ER, et al.:Antibody-targeted chemotherapy with CMC-544:a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103:1807-1814, 2004

• 15) Tobinai K, Ogura M, Hatake K, et al.:Phase I and pharmacokinetic study of inotuzumab ozogamicin (CMC-544) as a single agent in Japanese patients with follicular lymphoma pretreated with rituximab. Blood (ASH Annual Meeting Abstracts), 112:1565, 2008

• 16) Gallamini A, Zaja E patti C, et al.:Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma:results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007

• 17) Peleg AY, Husain S, Kwak EJ, et al.:Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody Clin Infect Dis 44:204-212, 2007
  pubmed

• 18) Rodig SJ, Abramson JS, Pinkus GS, et al.:Heterogeneous CD-52 expression among hematologic neoplasms:implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 12:7174-7179, 2006

• 19) Rummel MJ, Al-Batran SE, Kim SZ, et al.:Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005

• 20) Carducci MA, Musib L, Kies MS, et al.:phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24:4092-4099, 2006

• 21) Robertson MJ, Kahl BS, Vose JM, et al.:Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25:1741-1746, 2007
  pubmed

• 22) Ishida T, Ueda R:CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97:1139-1146, 2006
  pubmed

• 23) Olsen EA, Kim YH, Kuzel TM, et al.:Phase II b multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115, 2007
  pubmed

• 24) Balakrishnan K, Nimmanapalli R, Ravandi E et al.:Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 108:2392-2398, 2006

• 25) O'Connor OA, Hamlin PA, Portlock C, et al.:Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139:425-428, 2007

P.94 掲載の参考文献

• 1) Seam P, Juweid, Cheson BD, et al.:The role of FDG-PET scans in patients with lymphoma. Blood 110:3507-3516, 2007
  pubmed

• 2) Schoder H, Noy A, Gonen M, et al.:Intensity of 18 fluorode-oxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23:4643-4651, 2005

• 3) Cheson BD, Pfistner B, Juweid ME, et al.:Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
  pubmed

• 4) Elstrom R, Guan L, Baker G, et al.:Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876, 2003
  pubmed

• 5) Kako S, Izutsu K, Ota Y, et al.:FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685-1690, 2007

• 6) Bangerter M, Moog E Buchmann I, et al.:Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9:1117-1122, 1998

• 7) Juweid ME, Wiseman GA, Vbse JM, et al.:Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661, 2005

• 8) Juweid ME, Stroobants S, Hoekstra OS, et al.:Use of positron emission tomography for response assessment of lymphoma:consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007

• 9) Kobe C, Dietlein M, Franklin J, et al.:Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989-3994, 2008
  pubmed

• 10) Gallamini A, Hutchings M, Rigacci L, et al.:Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
  pubmed

• 11) Haioun C, Itti E, Rahmouni A, et al.:[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma:an early prognostic tool for predicting patient outcome. Blood 106:1376-1381, 2005
  pubmed

• 12) Lin C, Itti E, Haioun C, et al.:Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma:SUV-based assessment versus visual analysis. J Nucl Med 48:1626-1632, 2007
  pubmed

• 13) Zinzani PL, Stefoni V, Tani M, et al.:Role of [18F] Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. J Clin Oncol 27:1781-1787, 2009
  pubmed

• 14) Jerusalem G, Beguin Y, Fassotte ME et al.:Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14:123-130, 2003
  pubmed

P.101 掲載の参考文献

• 1) Chinn PC, Leonard JE, Rosenberg J, et al.:Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 15:1017-1025, 1999
  pubmed

• 2) Press OW:Physics for practitioners:the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma. Semin Hematol 37 (4 suppl 7):2-8, 2000

• 3) Wiseman GA, Leigh B, Erwin WD, et al.:Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94(4 suppl):1349-1357, 2002

• 4) Witzig TE, White CA, Wiseman GA, et al.:Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999

• 5) Gordon LI, Molina A, Witzig T, et al.:Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+B-cell lymphoma:long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004
  pubmed

• 6) Witzig TE, Gordon LI, Cabanillas F et al.:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002

• 7) Wiseman GA, Gordon LI, Multani PS, et al.:Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocy-topenia:a phase II multicenter trial. Blood 99:4336-4342, 2002

• 8) Witzig TE, Flinn IW, Gordon LI, et al.:Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
  pubmed

• 9) Schilder RJ, Emmanouilides C, Vb K, et al.:Yttrium 90 ibritumomab tiuxetan (Zebarin(R)) is safe and effective in older patients with relapsed or refractory NHL. Proc ASCO 23:(abstract 6562), 2005

• 10) Witzig TE, White CA, Gordon LI, et al.:Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003

• 11) Bennett JM, Kaminski MS, Leonard JB et al.:Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 1131 tositumomab. Blood 105:4576-4582, 2005

• 12) Watanabe T Terui S, Itoh K, et al.:Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90) Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci 96:903-910, 2005
  pubmed

• 13) Tobinai K, Watanabe T, Ogura M, et al.:Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100:158-164, 2009
  Medical*Online
  pubmed

• 14) Zinzani PL, d'Amore E Bombardieri E, et al.:Consensus conference:implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice-report of a European workshop. Eur J Cancer 44:366-373, 2008

• 15) Morschhauser E Radford J, Van Hoof A, et al.:Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008

• 16) Zinzani PL, Tani M, Fanti S, et al.:A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 112:856-862, 2008
  pubmed

各論

P.108 掲載の参考文献

• 1) Tonegawa S, Steinberg C, Dube S et al.:Evidence for somatic generation of antibody diversity Proc Natl Acad Sci USA 71:4027-4031, 1974
  pubmed

• 2) Batista FD, Harwood NE:The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9:15-27, 2009

• 3) Nakamura N, Abe M:Histogenesis of CD5-positive and CD5-negative B-cell neoplasms on the aspect of somatic mutation of immunoglobulin heavy chain gene variable region. Fukushima J Med Sci 49:55-67, 2003
  pubmed

• 4) Broyde A, Boycov O, Strenov Y, et al.:Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 84:338-343, 2009
  pubmed

• 5) Kuppers R, Dalla-Favera R:Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580-5594, 2001

• 6) Nakamura N, Abe M:Richter syndrome in B-cell chronic lymphocytic leukemia. Pathol Int 53:195-203, 2003

P.112 掲載の参考文献

• 1) Liu L, McGavran L, Lovell MA, et al.:Nonpositive terminal deoxynucleotidyl transferase in pediatric precursor B-lymphoblastic leukemia. Am J Clin Pathol 121:810-815, 2004
  pubmed

• 2) Harewood L, Robinson H, Harris R, et al.:Amplification of AMLI on a duplicated chromosome 21 in acute lymphoblastic leukemia:a study of 20 cases. Leukemia 17:547-553, 2003

• 3) Hashimoto M, Yamashita Y, Mori N:Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol 197:341-347, 2002
  pubmed

• 4) Cobaleda C, Busslinger M:Developmental plasticity of lymphocytes. Curr Opin Immunol 20:139-148, 2008
  pubmed

• 5) Meyer C, Kowarz E, Hofmann J, et al.:New insights to the MLL recombinome of acute leukemias. Leukemia 23:1490-1499, 2009

• 6) Pui CH, Crist WM, Look AT:Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76:1449-1463, 1990
  pubmed

• 7) Harrison CJ:The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. Blood Rev 15:49-59, 2001
  pubmed

• 8) Yeoh EJ, Ross ME, Shurtleff SA, et al.:Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143, 2002
  pubmed

• 9) Grimaldi JC, Meeker TC:The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 73:2081-2085, 1989

• 10) LeBrun DP:E2A basic helix-loop-helix transcription factors in human leukemia. Front Biosci 8:s206-s222, 2003
  pubmed

• 11) Meijerink JP, den Boer ML, Pieters R:New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol 46:16-23, 2009
  pubmed

P.113 掲載の参考文献

• i) 岡本昌隆:2. 活動状況・各種統計. 悪性リンパ腫・臨床と病理-ALTSG の研究から-, 平野正美編, 先端医学社, 東京, 2005, pp14-28

• ii) 神野正敏:4. リンパ芽球白血病/リンパ腫. 悪性リンパ腫・臨床と病理-ALTSG の研究から-, 平野正美編, 先端医学社, 東京, 2005, pp146-150

P.122 掲載の参考文献

• 1) Ganti AK, Weisenburger DD, Smith LM, et al.:Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy:the Nebraska Lymphoma Study Group Experience. Ann Oncol 17:920-927, 2006

• 2) Martinez AE, Lin L, Dunphy CH:Grading of follicular lymphoma:comparison of routine histology with immunohistochemistry Arch Pathol Lab Med 131:1084-1088, 2007
  pubmed

• 3) Wang SA, Wang L, Hochberg EP, et al:Low histologic grade follicular lymphoma with high proliferation index:morphologic and clinical features. Am Surg Pathol 29:1490-1496, 2005
  pubmed

• 4) Karube K, Guo Y, Suzumiya J, et al.:CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 109:3076-3079, 2007
  pubmed

• 5) Agrawal R, Wang J:Pediatric follicular lymphoma:a rare clinicopathologic entity. Arch Pathol Lab Med 133:142-146, 2009
  pubmed

• 6) Kojima M, Nakamura S, Ichimura K, et al.:Follicular lymphoma of the salivary gland:a clinicopathological and molecular study of six cases. Int J Surg Pathol 9:287-293, 2001
  pubmed

• 7) Nakamura S, Ichimura K, Sato Y, et al.:Follicular lymphoma frequently originates in the salivary gland. Pathol Int 56:576-583, 2006
  pubmed

• 8) Bacon CM, Ye H, Diss TC, et al.:Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 31:1050-1058, 2007
  pubmed

• 9) Bacon CM, Diss TC, Ye H, et al.:Follicular lymphoma of the thyroid gland. Am J Surg Pathol 33:22-34, 2009
  pubmed

• 10) Cong P, Raffeld M, Teruya-Feldstein J, et al.:In situ localization of follicular lymphoma:description and analysis by laser capture microdissection. Blood 99:3376-3382, 2002
  pubmed

• 11) Willemze R, Jaffe ES, Burg G, et al:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
  pubmed

• 12) Willemze R, Kerl H, Sterry W, et al.:EORTC classification for primary cutaneous lymphomas:a proposal from the cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997

• 13) Grange E Bekkenk MW, Wechsler J, et al.:Prognostic factors in primary cutaneous large B-cell lymphomas:a European multicenter study. J Clin Oncol 19:3602-3610, 2001

P.137 掲載の参考文献

• 1) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて . 日本リンパ網内系雑誌 49:86, 2009

• 2) Freedman AS:Biology and Management of Histologic Transformation of Indolent Lymphoma. Hematology Am Soc Hematol Educ Program:314-320, 2005
  pubmed

• 3) 中村栄男:A. 非ホジキンリンパ腫[1]B細胞a.普遍的な型3濾胞性リンパ腫. 新・悪性リンパ腫アトラス, 須知泰山, 菊池昌弘, 三方淳男ほか編, 文光堂, 東京, 2000, pp59-67

• 4) Yasukawa M, Bando S, Dolken G, et al.:Low frequency of BCL-2/JH translocation in peripheral blood lymphocytes of healthy Japanese individuals. Blood 99:486-488, 2001

• 5) Harris NL, Swerdlow SH, Jaffe ES, et al.:Follicular lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC, Lyon, 2008, pp220-226

• 6) Horning SJ:Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 (suppl 5):75-88, 1993

• 7) Rosenberg SA:Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphoma:challenges and opportunities. J Clin Oncol 3:299-310, 1985
  pubmed

• 8) Gine E, Montoto S, Bosch E et al.:The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological sub-type are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539-1545, 2006

• 9) Anderson JR, Vose JM, Bierman PJ, et al.:Clinical features and prognosis of follicular large-cell lymphoma:a report from the Nebraska Lymphoma Study Group. J Clin Oncol 11:218-224, 1993

• 10) Bartlett NL, Rizeq M, Dorinan RE et al.:Follicular large cell lymphoma:intermediate or low grade?J Clin Oncol 12:1349-1357, 1994

• 11) Weider RB, Jones D, Tucker SL, et al.:Long term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51:1219-1227, 2001

• 12) Seymour JF pro B, Fuller LM, et al.:Long-term follow-up of a prospective study of combined modality therapy for stage I II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-2122, 2003

• 13) Horning SJ, Rosenberg SA:The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 311:1471-1475, 1984
  pubmed

• 14) Young RC, Longo DL, Glatstein E, et al.:The treatment of indolent lymphomas:watchful waiting v aggressive combined modality treatment. Semin Hematol 25 (2 suppl 2):11-16, 1988

• 15) Salles GA:Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program:216-225, 2007
  pubmed

• 16) Dana BW, Dahlberg S, Nathwani BN, et al.:Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
  pubmed

• 17) Peterson BA, Petroni GR, Frizzera G, et al.:Prolonged single-agent versus combination chemotherapy in Indolent follicularlymphomas:a study of the cancer and leukemia group B. J Clin Oncol 21:5-15, 2003

• 18) Montoto S, Moreno C, Domingo-Domenech E, et al.:High clinical and molecular response rates with fuludarabine, cyclo-phosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Hematologica 93:207-214, 2008

• 19) Rummel MJ, Chow KU, Karakas T, et al.:Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle cell and low grade non Hodgkin's lymphoma. European J Cancer 38:1739-1746, 2002

• 20) Witzig TE, Vukov AM, Habermann TM, et al.:Rituximab therapy for patients with newly diagnosed, advanced-stage, follicu-lar grade 1 non-Hodgkin's lymphoma:A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:1103-1108, 2005

• 21) Davis TA, Grillo-Lopwz AJ, White CA, et al.:Rituximab anti CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000

• 22) Hiddemann W, Buske C, Dreyling M, et al.:Treatment strategies in follicular lymphomas:current status and future perspectives. J Clin Oncol 26:6394-6399, 2005
  pubmed

• 23) Niitsu N, Hayama M, Okamoto M, et al.:Phase I study of rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clin Cancer Res 10:4077-4082, 2004
  pubmed

• 24) Witzig TE, Gordon LI, Cabanillas F et al.:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radio-immunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-1463, 2002

• 25) Press OW, Unger JM, Braziel RM, et al.:Phase II trial of CHOP chemotherapy followed by tositumonab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma; Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006

• 26) Zinzani PL, Tani M, Pulsoni A, et al.:Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial:phase II non-randomised trial (FLUMIZ). Lancet Oncol 9:352-358, 2008
  pubmed

• 27) Freedman AS, Neuberg D, mauch P, et al.:Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94;3325-3333, 1999
  pubmed

• 28) Bierman PJ, Vose JM, Anderson JR, et al:High-dose therapy and autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
  pubmed

• 29) William CD, Godstone AH, Pearce RM, et al.:Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma:a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 14:2454-2464, 1996

• 30) Hunault-Berger m, Ifrah N, Solal-Celigny P, et al.:Intensive therapies in follicular non-Hodgkin lymphomas. Blood 100:1141-1152, 2002
  pubmed

• 31) Schouten HC, Qian W, Kvaloy S, et al.:high-dose therapy improves progression-free surviaval and survival in relapsed follicular non-Hodgkin's lymphoma:results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003

• 32) Freedman As, Gribben JG Neuberg D, et al.:High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
  pubmed

• 33) van Besien K, Sobocinski KA, Rowlings PA., et al.:Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998
  pubmed

• 34) van Besien K, Loberiza FR Jr, bajorunaite R, et al.:Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529,2003
  pubmed

• 35) Robinson SP, Goldstone AH, Mackinnon S, et al.:Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation:an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316, 2002
  pubmed

• 36) Solal-Celigny P, Roy P, Colombat P, et al.:Follicular lymphoma International Prognostic Index. Blood 104:1258-1265, 2004
  pubmed

• 37) Tilly H, Rossi A, Stamatoullas A, et al.:Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84:1043-1049, 1994
  pubmed

• 38) Dave SS, Wright G, Tan B, et al.:Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
  pubmed

• i) Tilly H, Rossi A, Stamatoullas A, et al.:Prognostic value of chronosomal abnormalities in follicular lymphoma. Blood 84;1043-1049, 1994
  pubmed

P.143 掲載の参考文献

• 1) Yoshino T, Miyake K, Ichimura K, et al.:Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 24:688-693, 2000
  pubmed

• 2) Sato Y, Ichimura K, Tanaka T, et al.:Duodenal follicular lymphoma share common characteristics with mucosa-associated lymphoid tissue lymphomas. J Clin Pathol 61:377-381, 2008
  pubmed

• 3) Nakamura S, Ichimura K, Sato Y, et al.:Follicular lymphoma frequently originates in the salivary gland. Pathol Int 56:576-583, 2006
  pubmed

• 4) Bacon CM, Diss TC, Ye H, et al.:Follicular lymphoma of the thyroid gland. Am J Surg Pathol 33:22-34, 2009
  pubmed

• 5) Damaj G, Verkarre V Delmer A, et al.:Primary follicular lymphoma of the gastrointestinal tract:a study of 25 cases and a literature review. Ann Oncol 14:623-629, 2003

• 6) Takata K, Sato Y, Nakamura N, et al.:Duodenal and nodal follicular lymphomas are distinct:The former lacks activation-induced cytidine deaminase and follicular dendritic cells despite ongoing somatic hypermutations. Mod Pathol 22:940-949, 2009
  pubmed

• 7) Aarts WM, Bende RJ, Steenbergen EJ, et al.:Variable heavy chain gene analysis of follicular lymphomas:correlation between heavy chain isotype expression and sornatic mutation load. Blood 95:2922-2929, 2000

• 8) Sato Y, Nakamura N, Nakamura S, et al.:Deviated VH4 immunoglobulin:gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at other sites, but is not found in thyroid diffuse large B-cell lymphomas. Mod Pathol 19:1578-1584, 2006

• 9) Bende RJ, Smit LA, Bossenbroek JG, et al.:Primary follicular lymphoma of the small intestine:α4β7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B-cells. Am J Pathol 162:105-113, 2003

• 10) Liu YX, Yoshino T, Ohara N, et al.:Loss of expression of α4β7integrin and L-selectin is associated with high-grade progression of low-grade MALT lymphoma. Mod Pathol 114:798-805, 2001

• 11) Toyoda H, Yamaguchi M, Nakamura S, et al.:Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori. Gastrointest Endosc 54:92-96, 2001
  pubmed

P.152 掲載の参考文献

• 1) Swerdlow SH, Williams ME:From centrocytic to mantle cell lymphoma. a clinicopathologic and molecular review of 3 decades. Hum Pathol 33:7-20, 2002
  pubmed

• 2) Swerdlow SH, Campo E, Seto M, et al.:Mantle cell lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp229-232

• 3) Tiemann M, Schrader C, Klapper W, et al.:Histopathology, cell proliferation indices, and clinical outcome in 304 patients with mantle cell lymphoma (MCL). a clinicopathologic study from the European MCL Network. Br J Haematol 131:29-38, 2005
  pubmed

• 4) Norton AJ, Matthews J, Pappa V, et al.:Mantle cell lymphoma:natural history defined in a serially biopsied population over 20-year period. Ann Oncol 6:249-256, 1995

• 5) Swerdlow SH, Nathwani BN, Berger E et al.:Mantle cell lymphoma. In:WHO Classification of Tumours. Pathology and Genetics Tumours of Haematopoietic and Lymphoid Tissues, ed by Jaffe ES, Harris NL, Stein H, et al., IARC Press, Lyon, 2001, pp168-170

• 6) Liu Z, Dong HY, Gorczyca W, et al.:CD5-mantle cell lymphoma. Am J Clin Pathol 118:216-224, 2002

• 7) Schlette L, Fu K, Medeiros LJ:CD23 expression in mantle cell lymphoma:clinicopathologic features of 18 cases. Am J Clin Pathol 120:760-766, 2003

• 8) Dong HY, Gorczyca W, Liu Z, et al.:B-cell lymphomas with co-expression of CD5 and CD10. Am J Clin Pathol 119:218-230, 2003

• 9) Sriganeshan V, Blom TR, Weissmann DJ:A unique case of mantle cell lymphoma with an aberrant CD5-/CD10+immuno-phenotype and typical morphology. Arch Pathol Lab Med 132:1346-1349, 2008

• 10) Cheuk W, Wong KO, Wong CS, et al.:Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody Am J Surg Pathol 28:801-807, 2004

• 11) Determann O, Hoster E, Ott G, et al.:Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunotherapy:results from randomized trails of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111:2385-2387, 2008

• 12) Romaguera JE, Medeiros LJ, Heagemeister FB, et al.:Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97:586-591, 2003

• 13) Salar A, Juanpere N, Bellosillo B, et al.:Gastrointestinal involvement in mantle cell lymphoma. a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 30:1274-1280, 2006
  pubmed

P.164 掲載の参考文献

• 1) Weisenburger DD, Kim H, Rappaport H, et al.:Mantle-zone lymphoma:a follicular variant of intermediate lymphocytic lymphoma. Cancer 49:1429-1438, 1982
  pubmed

• 2) Banks PM, Chan K, Cleary ML, et al.:Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637-640,1992

• 3) Lymphoma Study Group of Japanese Pathologist:The World Health Organization Classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000

• 4) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO Classification分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 5) Hummel M, Tamaru J, Kalvelage B, et al.:Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle. Blood 84:403-407, 1994
  pubmed

• 6) Bosch F, Lopez-Guillermo A, Campo E, et al.:Mantle cell lymphoma:presenting features, response to therapy, and prognosotic factors. Cancer 82:567-575, 1998
  pubmed

• 7) Weisenburger DD, Vose JM, Greiner TC, et al.; Mantle cell lymphoma. A clinicopathologic study of 68 cases from Nebraska Lymphoma Study Group. Am J Hematol 64:190-196, 2000

• 8) 二村聡, 松野吉宏:10. マントル細胞リンパ腫. 最新・悪性リンパ腫アトラス, 菊池昌広, 森茂郎編, 文光堂, 東京, 2004, pp154-161

• 9) Yatabe Y, Suzuki R, Robinai K, et al.:Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95:2253-2261, 2000

• 10) Fisher RI, Dahlberg S, Nathwani BN, et al.:A Clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma(including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):85:1075-1082, 1995
  pubmed

• 11) The Non-Hadgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997

• 12) Leithc HA, Gascoyne RD, Chhanabhai M, et al.:Limited-stage mantle-cell lymphoma. Ann Oncol 14:1555-1561, 2003

• 13) Meusers P, Engelhard M, Bartels H, et al.:Multicentre randomized therapeutic trial for advanced centrocytic lymphoma:Anthracycline dose not improve the prognosis. Hematol Oncol 7:365-380, 1989

• 14) Zucca E, Roggero E, Pinotti G, et al.:Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995
  pubmed

• 15) Ghielmini M, Schmitz SE Burki K, et al.:The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11 (suppl 1):123-126, 2000

• 16) Foran JM, Rohatiner AZ, Cunningham D, et al.:European phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000

• 17) Ghielmini, M, Schmitz SE Cogliatti S, et al.:Effect of single-agent rituximab given at the standard schedule or prolonged treatment in patients with mantle cell lymphoma:a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705-711, 2005

• 18) Howard OM, Gribben JG, Neuberg DS, et al.:Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma:molecular complete response are not predictivej of progression free survival. J Clin Oncol 20:1288-1294, 2002

• 19) Lenz G, Dreyling M, Hoster E, et al.:Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone signifanctly improves response and time to treatment failure, but not long-term outcome in patients to treatment failure, but not long term outcome in patients with previously untreated mantle cell lymphoma:Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005

• 20) Romaguera JE, Fayad L, Rodriguez MA, et al.:High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
  pubmed

• 21) Weigert O, Unterhalt M, Hiddemann W, et al.:Current management of mantle cell lymphoma. Drugs 67:1689-1702, 2007
  pubmed

• 22) Forstpointner R, Dreyling M, Repp R, et al.:The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 104:3064-3071, 2004

• 23) Forstpointner R, Unterhalt M, Dreyling M, et al.:Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 108:4003-4008, 2006

• 24) Zhou Y, Zhang L, Romaguera J, et al.:Immunotherapy in mantle cell lymphoma:Anti-CD20-based therapy and beyond. Am J Hematol 83:144-149, 2008
  pubmed

• 25) Freedman AS, Neuberg D, Gribben JG, et al.:High-dose Chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma:no evidence for long-term remission. J Clin Oncol 16:13-18, 1998
  pubmed

• 26) Vose JM, Bierman PJ, Weisenburger DD, et al.:Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 6:640-645, 2000
  pubmed

• 27) Decaudin D, Brousse N, Brice P, et al.:Efficacy of autologous stem cell transplantation in mantle cell lymphoma:a 3-year follow-up study. Bone Marrow Transplant 25:251-256, 2000
  pubmed

• 28) Khouri IF, Romaguera J, Kantarjian H, et al.:Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation:an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998
  pubmed

• 29) Lefrere E Delmer A, Levy V, et al.:Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma:an update of prospective study. Haematologica 89:1275-1276, 2004

• 30) Dreyling M, Lenz G, Hoster E, et al.:Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma:results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
  pubmed

• 31) Gill S, Ritchie D:Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 49:398-409, 2008
  pubmed

• 32) Kasamon YL:Blood or marrow transplantation for mantle cell lymphoma. Curr Opin Oncol 19:128-135, 2007

• 33) Khouri IF Lee MS, Saliba RM, et al.:Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21:4407-4412, 2003
  pubmed

• 34) Robinson SP, Goldstone AH, Mackinnon S, et al.:Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation:an analysis from Lyhmphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316, 2002
  pubmed

• 35) Herold M, Schulze A, Niederwieser D, et al.:Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma:results of randomized phase III trial (OSHO#19). J Cancer Res Clin Oncol 132:105-112, 2006

• 36) Samaha H, Dumontet C, Ketterer N, et al.:Mantle cell lymphoma:a retrospective study of 121 cases. Leukemia 12:1281-1287, 1998
  pubmed

• 37) Hoster E, Dreyling M, Klapper W, et al.:A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008
  pubmed

• 38) Shah JJ, Fayad L, Romaguera J:Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 112:2583-2584, 2008

• i) Oinonen R, Franssila K, Elonen E:Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 78:145-149, 1999
  pubmed

P.173 掲載の参考文献

• 1) Campo E, Pileri SA, Jaffe ES, et al.:Nodal marginal zone lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp218-219

• 2) Isaacson PG, Nathwani BN, Piris MA, et al.:Nodal marginal zone B-cell lymphoma. In:WHO Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed by Jaffe ES, Hards NL, Stein H, et al., IARC Press, Lyon, 2001, p161

• 3) Sheibani K, Sohn CC, Burke JS, et at.:Monocytoid B-cell lymphoma. A novel B-cell neoplasm. Am J Pathol 124:310-318, 1986

• 4) Cousar JB, McGinn DL, Glick AD, et al.:Report of an unusual lymphoma arising from parafollicular B lymphocytes (PBLs) or so-called "monocytoid" lymphocytes. Am J Clin Pathol 87:121-128, 1987
  pubmed

• 5) Nizze H, Cogliatti SB, von Schilling C, et al.:Monocytoid B-cell lymphoma:morphological variants and relationship to low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue. Histopathology 18:403-414, 1991
  pubmed

• 6) Nathwani BN, Mohrmann RL, Brynes RK, et al.:Monocytoid B-cell lymphoma:an assessment of diagnostic criteria and a perspective on histogenesis. Hum Pathol 23:1061-1071, 1992

• 7) Davis GG, York JC, Glick AD, et al.:Plasmacytic differentiation in parafollicular (monocytoid) B-cell lymphoma. A study of 12 cases. Am J Surg Pathol 16:1066-1074, 1992
  pubmed

• 8) Nathwani BN, Anderson JR, Armitage JO, et al.:Marginal zone B-cell lymphoma:A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 17:2486-2492, 1999
  pubmed

• 9) Camacho FI, Algara P, Mollejo M, et al.:Nodal marginal zone lymphoma:A heterogeneous tumor. A comprehensive analysis of a series of 27 cases. Am J Surg Pathol 27:762-771, 2003
  pubmed

• 10) Traverse-Glehen A, Felman P, Callet-Bauchu E, et al.:A clinicopathologic study of nodal marginal zone B-cell lymphoma. A report of 21 cases. Histopathology 48:162-173, 2006
  pubmed

• 11) Kojima M, Inagaki H, Motoori T, et al.:Clinical implications of nodal marginal zone B-cell lymphoma among Japanese. A study of 65 cases. Cancer Sci 98:44-49, 2007
  pubmed

• 12) Taddesse-Heath L, Pittaluga S, Sorbara L, et al.:Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol 27:522-531, 2003

• 13) Attygalle AD, Liu H, Shirali S, et al.:A typical marginal zone hyperplasia of mucosa-associated lymphoid tissue:A reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood 104:3343-3348, 2004

• 14) Campo E, Miquel R, Krenacs L, et al.:Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol 23:59-68, 1999
  pubmed

• 15) Kojima M, Nakamura S, Itoh H, et al.:Occurrence of monocytoid B-cells in reactive lymph node lesions. Pathol Res Pract 194:559-565, 1998
  pubmed

• 16) Gupta D, Lim MS, Medeiros LJ, et al.:Small lymphocytic lymphoma with perifollicular, marginal zone, or interfollicular differentiation. Mod Pathol 13:1161-1166, 2000
  pubmed

• 17) Osborne BM, Butler JJ, Mackay B:Sinusoidal large cell ("histiocytic") lymphoma. Cancer 46:2484-2491, 1980
  pubmed

• 18) Lai R, Medeiros LJ, Dabbagh L, et al.:Sinusoidal CD30-positive large B-cell lymphoma:a morphologic mimic of anaplastic large cell lymphoma. Mod Pathol 13:223-228, 2000

P.178 掲載の参考文献

• 1) Mollejo M, Camacho FI, Algara P, et al.:Nodal and splenic marginal zone B cell lymphomas. Hematol Oncol 23:108-118, 2005

• 2) Arcaini L, Paulli M, Burcheri S, et al.:Primary nodal marginal zone B-cell lymphoma:clinical features and prognostic assessment of a rare disease. Br J Haematol 136:301-304, 2007
  pubmed

• 3) Kojima M, Inagaki H, Motoori T, et al.:Clinical implications of nodal marginal zone B-cell lymphoma among Japanese:study of 65 cases. Cancer Sci 98:44-49, 2007
  pubmed

• 4) Suarez F, Lortholary O, Hermine O, et al.:Infection-associated lymphomas derived from marginal zone B cells:a model of antigen-driven lymphoproliferation. Blood 107:3034-3044, 2006

• 5) Kahl B, Yang D:Marginal Zone Lymphomas:Management of Nodal, Splenic, and MALT NHL. Hematology Am Soc Hematol Educ Program:359-364, 2008
  pubmed

• 6) Zucca E, Bertoni E Stathis A, et al.:Marginal zone lymphomas. Hematol Oncol Clin North Am 22:883-901, 2008

• 7) Ferreri AJ, Zucca E:Marginal-zone lymphoma. Crit Rev Oncol Hematol 63:245-256, 2007
  pubmed

• 8) Aviles A, Delgado S, Huerta-Guzman J:Marginal zone B cell lymphoma of the parotid glands:results of a randomised trial comparing radiotherapy to combined therapy. Eur J Cancer B Oral Oncol 32B:420-422, 1996
  pubmed

• 9) Koh LP, Lim LC, Thng CH:Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 17:225-228, 2000

• 10) Berger F, Felman P, Thieblemont C, et al.:Non-MALT marginal zone B-cell lymphomas:a description of clinical presentation and outcome in 124 patients. Blood 95:1950-1956, 2000

• 11) Economopoulos T, Psyrri A, Fountzilas G, et al.:Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation:promising results in marginal zone lymphoma. Leuk Lymphoma 49:68-74, 2008
  pubmed

• 12) Fisher RI, Dahlberg S, Nathwani BN, et al.:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):a South-west Oncology Group study. Blood 85:1075-1082, 1995

• 13) Nathwani BN, Anderson JR, Armitage JO, et al.:Marginal zone B-cell lymphoma:A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 17:2486-2492, 1999
  pubmed

• 14) Thieblemont C, Coiffier B:Management of marginal zone lymphomas. Curr Treat Options Oncol 7:213-222, 2006
  pubmed

• 15) Camacho FI, Algara P, Mollejo M, et al.:Nodal marginal zone lymphoma:a heterogeneous tumor:a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 27:762-771, 2003
  pubmed

• 16) Petit B, Chaury MP, Le Clorennec C, et al.:Indolent lymphoplasmacytic and marginal zone B-cell lymphomas:absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica 90:200-206, 2005

P.182 掲載の参考文献

• 1) Schmid C, Kirkham N, Diss T, et al.:Splenic marginal zone cell lymphoma. Am J Surg Pathol 16:455-466, 1992
  pubmed

• 2) Thieblemont C, Felman P, Calle-Bauchu E, et al.:Splenic marginal-zone lymphoma:a distinct clinical and pathological entity. Lancet Oncol 4:95-103, 2003

• 3) Matutes E, Oscier D, Montalban CF, et al.:Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22:487-495, 2008

• 4) Mele A, Pulsoni A, Bianco E, et al.:Hepatitis C virus and B-cell non-Hodgkin lymphomas:an Italian multicenter case control study. Blood 102:996-999, 2003

• 5) Gimeno E, Salido M, Sole F, et al.:CD5 negative and CD5 positive splenic marginal B-cell lymphomas have differential cytogenetic patterns. Leuk Res 29:981-982, 2005
  pubmed

• 6) Arcaini L, Zibellini S, Passamonti f, et al.:Splenic marginal zone lymphoma:Clinical clustering of immunoglobin heavy chain repertoires. Blood Cells Mol Dis 42:286-291, 2009
  pubmed

• 7) Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma:a description of a series of 12 cases. Am J Surg Pathol 25:1268-1276, 2001

P.190 掲載の参考文献

• 1) Alizadeh AA, Eisen MB, Davis RE, et al.:Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
  pubmed

• 2) Rosenwald A, Wright G, Chan WC, et al.:Lymphoma/Leukemia Molecular Profiling Project:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002

• 3) Lenz G, Wright G, Dave SS, et al.:Lymphoma/Leukemia Molecular Profiling Project:Stromal gene signatures in large B-cell lymphomas. N Engl J Med 359:2313-2323, 2008

• 4) Yamaguchi M, Seto M, Okamoto M, et al.:De novo CD5+diffuse large B-cell lymphoma:a clinicopathologic study of 109 patients. Blood 99:815-821, 2002
  pubmed

• 5) Kobayashi T, Yamaguchi M, Kim S, et al.:Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5-diffuse large B-cell lymphomas Cancer Res 63:60-66, 2003

• 6) Tagawa H, Tsuzuki S, Suzuki R, et al.:Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma:camparison between CD5-positive and CD5-negative cases. Cancer Res 64:5948-5955, 2004

• 7) Yoshioka T, Miura I, Kume S, et al.:Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma:chromosome aberrations affecting 8p21 and 11q13 cnstitute major subgroups with different overall survival. Genes Chromosomes Cancer 42:149-157, 2005

• 8) Nakamura N, Nakamura S, Yamaguchi M, eta al.:CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region. Int J Hematol 81:58-61, 2005

• 9) Hyo R, Tomita N, Takeuchi K, et al.:The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol, 2009 (in press)

• 10) Hans CP, Weisenburge DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004

• 11) Muris JJ, Meijer CJ, Vos W, et al.:Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208:714-723, 2006
  pubmed

• 12) Choi WW, Weisenburger DD, Greiner TC, et al.:A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15:5494-5502, 2009
  pubmed

• 13) Houldsworth J, Mathew S, Rao PH, et al.:REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 87:25-29, 1996
  pubmed

• 14) Lenz G, Davis RE, Ngo VN, et al.:Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676-1979, 2008
  pubmed

P.202 掲載の参考文献

• 1) Stein H, Warnke RA, Chan WC, et al.:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008

• 2) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 3) Hunt KE, Reichard KK:Diffuse large B-cell lymphoma. Arch Pathol Lab Med 132:118-124, 2008
  pubmed

• 4) Hans CP, Weisenburger DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
  pubmed

• 5) Niitsu N, Okamoto M, Nakamura N, et al.:Prognostic impact of chromosomal alteration of 3q27 on nodal B-cell lymphoma:Correlation with histology, immunophenotype, karyotype, and clinical outcome in 329 consecutive patients. Leuk Res 31:1191-1197, 2007
  pubmed

• 6) Niitsu N, Okamoto M, Miura I, et al.:Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci, 2008 (in press)

• 7) Niitsu N, Okamoto M, Miura I, et al.:Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23:777-783, 2009

• 8) Alizadeh AA, Eisen MB, Davis RE, et al.:Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403:503-511, 2000
  pubmed

• 9) Tagawa H, Suguro M, Tsuzuki S, et al.:Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106:1770-1777, 2005
  pubmed

• 10) Lossos IS, Czerwinski DK, Alizadeh AA, et al.:Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004

• 11) Rosenwald A, Wright G, Chan WC, et al.:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
  pubmed

• 12) Miller TP, Dahlberg S, Cassady JR, et al.:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
  pubmed

• 13) Horning SJ, Weller E, Kim K, et at.:Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma:Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032-3038, 2004

• 14) Bonnet C, Fillet G, Mounier N, et al.:CHOP alone compa red with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007

• 15) Reyes E Lepage E, Ganem G, et al.:ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205, 2005

• 16) Persky DO, Unger JM, Spier CM, et al.:Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma:Southwest Oncology Group study OO14. J Clin Oncol 26:2258-2263, 2008

• 17) Pfreundschuh M, Trumper L, Osterborg A, et al.:CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffus e large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006

• 18) Fisher RI, Gaynor ER, Dahlberg S, et al.:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
  pubmed

• 19) Coiffier B, Lepage E, Briere J, et al.:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engt J Med 346:235-242, 2002

• 20) Feugier P, Van Hoof A, Sebban C, et al.:Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005

• 21) Sehn LH, Donaldson J, Chhanabhai M, et al.:Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005
  pubmed

• 22) Pfreundschuh M, Schubert J, Ziepert M, et al.:Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
  pubmed

• 23) Pfreundschuh M, Trumper L, Kloess M, et al.:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004

• 24) Pfreundschuh M, Trumper L, Kloess M, et al.:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004

• 25) Brusamolino E, Maffioli M, Bonfichi M, et al.:Front-line therapy for nonlocalized diffuse large B-cell lymphoma:what has been demonstrated and what is yet to be established. Future Oncol 4:199-210, 2008
  pubmed

• 26) Tilly H, Lepage E, Coiffier B, et al.:Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003

• 27) Niitsu N, Okamoto M, Aoki S, et al.:Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol 85:374-380, 2006
  pubmed

• 28) Philip T, Guglielmi C, Hagenbeek A, et al.:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
  pubmed

• 29) Kewalramani T, Zelenetz AD, Nimer SD, et al.:Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004
  pubmed

• 30) Haioun C, Lepage E, Gisselbrecht C, et al.:Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma:final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000

• 31) Lenz G, Wright G, Dave SS, et al.:Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008

P.205 掲載の参考文献

• 1) Nakamura S, Jaffe ES, Swerdlow SH:EBV positive diffuse large B-cell lymphoma of the elderly In:WHO Classification Classtfication of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, pp243-244, 2008

• 2) Oyama T, Ichimura K, Suzuki R, et al.:Senile EBV+B-cell lymphoproliferative disorders:a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16-26, 2003
  pubmed

• 3) Oyama T, Yamamoto K, Asano N, et al.:Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group:a study of 96 patients. Clin Cancer Res 13:5124-5132, 2007

• 4) Asano N, Yamamoto K, Tamaru J, et al.:Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders:comparison with EBV-positive classical Hodgkin lymphoma in elderly patients. Blood 113:2629-2636, 2009
  pubmed

P.208 掲載の参考文献

• 1) Nakamura S, Ponzoni M, Campo E:Intravascular large B-cell lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp252-253

• 2) Asada N, Odawara J, Kimura S, et al.:Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc 82:1525-1527, 2007

• 3) Murase T, Yamaguchi M, Suzuki R, et al.:Intravascular large B-cell lymphoma (IVLBCL):a clinicopathologic study of 96 cases with special reference to the immunophenotypic hetero-geneity of CD5. Blood 109:478-485, 2007

• 4) Murase T, Nakamura S, Kawauchi K, et al.:An Asian variant of intravascular large B-cell lymphoma:clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated ith haemophagocytic syndrome. Br J Haematol 111:826-834, 2000

• 5) Murase T, Nakamura S:An Asian variant of intravascular lymphomatosis:an updated review of malignant histiocytosis-like B-cell lymphoma. Leuk Lymphoma 33:459-473, 1999

• 6) Murase T, Nakamura S, Tashiro K, et al.:Malignant-histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis:a report of five cases and review of the literature. Br J Haematol 99:656-664, 1997

• 7) Ponzoni M, Ferreri AJ, Campo E, et at.:Definition, diagnosis, and management of intravascular large B-cell lymphoma:Proposals and perspectives from an international consensus meeting. J Clin Oncol 25:3168-3173, 2007

• 8) Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma:results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195-1202, 2008
  pubmed

• 9) Takahashi E, Kajimoto K, Fukatsu T et al.:Intravascular large T-cell lymphoma:a case report of CD30-positive and ALK-negative anaplastic type with cytotoxic molecule expression. Virchows Arch 447:1000-1006, 2005

• 10) Shimada K, Matsue K, Yamamoto K, et al.:Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:3189-3195, 2008

P.212 掲載の参考文献

• 1) Perrone T, Frizzera G, Rosai J:Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol 10:176-191, 1986
  pubmed

• 2) Moldenhauer G, Popov SW, Wotschke B, et al.:AID expression identifies interfollicular large B cells as putative precur-sors of mature B-cell malignancies. Blood 107:2470-2473, 2006

• 3) Lymphoma Study Group of Japanese Pathologist. The World Health Organization classification of malignant lymphoma in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000

• 4) Paulli M, Strater J, Gianelli U, et al.:Mediastinal B-cell lymphoma:a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 30:178-187, 1999
  pubmed

• 5) Kanavaros B Gaulard P, Charlotte E et al.:Discordant expression of immunoglobulin and its associated molecule mb-1/ CD79a is frequently found in mediastinal large B cell lymphomas. Am J Pathol 146:735-741, 1995

• 6) Pileri SA, Gaidano G, Zinzani PL, et al.:Primary mediastinal B-cell lymphoma:high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB. 1, and PU. 1 in the absence of immunoglobulins. Am J Pathol 162:243-253, 2003
  pubmed

• 7) Calaminici M, Piper K, Lee AM, et al.:CD23 expression in mediastinal large B-cell lymphomas. Histopathology 45:619-624, 2004

• 8) de Leval L, Ferry JA, Falini B, et al.:Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma:evidence for derivation from germinal center B cells? Am J Surg Pathol 25:1277-1282, 2001

• 9) Copie-Bergman C, Gaulard P, Maouche-Chretien L, et al.:The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood 94:3567-3575, 1999

• 10) Rodig SJ, Savage KJ, LaCasce AS, et al.:Expression of TRAFI and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 31:106-112, 2007

• 11) Leithauser E Bauerle M, Huynh MQ, et al.:Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 98:2762-2770, 2001

• 12) Wessendorf S, Barth TE Viardot A, et al.:Further deline ation of chromosomal consensus regions in primary mediastinal B-cell lymphomas:an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 21:2463-2469, 2007

• 13) Rosenwald A, Wright G, Leroy K, et al.:Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862, 2003
  pubmed

• 14) Savage KJ, Monti S, Kutok JL, et al.:The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003

• 15) Traverse-Glehen A, Pittaluga S, Gaulard P, et al.:Mediastinal gray zone lymphoma:the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29:1411-1421, 2005

• i) Lazzarino M, Orlandi E, Paulli M, et al.:Primary mediastinal B-cell lymphoma with sclerosis:an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 11:2306-2313, 1993
  pubmed

• ii) De Sanctis V, Finolezzi E, Osti ME et al.:MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys 72:1154-1160, 2008

• iii) Jacobson JO, Aisenberg AC, Lamarre L et al.:Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy Cancer 62:1893-1898, 1998

P.219 掲載の参考文献

• 1) Batchelor T, Loeffle JS:Primary CNS lymphoma. J Clin Oncol 24:1281-1288, 2006

• 2) Bhagavathi S, Wilson JD:Primary central nervous system lymphoma. Arch Pathol Lab Med 132:1830-1834, 2008
  pubmed

• 3) Deckert M, Paulus W:Malignant Lymphomas. In:WHO Classification of Tumours of the Central Nervous System, ed by Louis DN, Ohgaki H, Wiestler OD, et al., IARC Press, Lyon, 2007, pp188-192

• 4) Abrey LE, Batchelor TT, Ferreri AJ, et al.:Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005
  pubmed

• 5) Camilleri-Broet S, Criniere E, Broet P, et al.:Auniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas:analysis of 83 cases. Blood 107:190-196, 2006

• 6) Ferreri AJ, Blay JY, Reni M, et al.:Prognostic scoring system for primary CNS lymphomas:the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266-272, 2003

• 7) Nelson DE Martz KL, Bonner H, et al.:non-Hodgkin's lymphoma of the brain:can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG):RTOG 8315. Int J Radiat Oncol Biol Phys 23:9-17, 1992

• 8) Shibamoto Y, Ogino H, Hasegawa M, et al.:Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 62:809-813, 2005
  pubmed

• 9) Abrey LE, Yahalom J, DeAngelis LM:Treatment for primary CNS lymphoma:the next step. J Clin Oncol 18:3144-3150, 2000
  pubmed

• 10) DeAngelis LM, Iwamoto FM:An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program:311-316, 2006

• 11) DeAngelis LM, Seiferheld W, Schold SC, et al.:Combination chemotherapy and radiotherapy for primary central nervous system lymphoma:Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643-4648, 2002

• 12) Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et at.:High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma:European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21:4483-4488, 2003

• 13) Ferreri AJ, Reni M, Pasini E et al.:A multicenter study of treatment of primary CNS lymphoma. Neurology 58:1513-1520, 2002

• 14) Pels H, Schmidt-Wolf IG, Glasmacher A, et al.:Primary central nervous system lymphoma:results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy J Clin Oncol 21:4489-4495, 2003
  pubmed

• 15) Abrey LE, Ben-Porat L, Panageas KS, et al.:Primary central nervous system lymphoma:the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711-5715, 2006

• 16) Omuro AM, DeAngelis LM, Yahalom J, et al.:Chemoradiotherapy for primary CNS lymphoma:an intent-to-treat analysis with complete follow-up. Neurology 64:69-74, 2005
  pubmed

P.224 掲載の参考文献

• 1) Delsol G, Campo E, Gascoyne RD, et al.:Alk-positive large B-cell lymphoma. In:WHO Classification Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris LN, et al., IARC Press, Lyon, 2008

• 2) Delsol G, Lamant L, Mariame B, et al.:A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 89:1483-1490, 1997

• 3) Gascoyne RD, Lamant L, Martin-Subero JI, et al.:ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements:report of 6 cases. Blood 102:2568-2573, 2003
  pubmed

• 4) De Paepe P, Baens M, van Krieken H, et al.:ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102:2638-2641, 2003

• 5) Reichard KK, McKenna RW, Kroft SH:ALK-positive diffuse large B-cell lymphoma:report of four cases and review of the literature. Mod Pathol 20:310-319, 2007
  pubmed

• 6) Lee HW, Kim K, Kim W, et al.:ALK-positive diffuse large B-cell lymphoma:report of three cases. Hematol Oncol 26:108-113, 2008
  pubmed

• 7) Momose S, Tamaru J, Kishi H, et al.:Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum Pathol 40:75-82, 2009
  pubmed

• 8) Beltran B, Castillo J, Salas R, et al.:ALK-positive diffuse large B-cell lymphoma:report of four cases and review of the literature. J Hematol Oncol 2:11, 2009

• 9) Wang WY, Ma ZG, Li GD, et al.:Diffuse large B-cell lymphoma with expression of anaplastic lymphoma kinase protein:clinicopathologic and immunohistochemical study of 5 cases. Zhonghua Bing Li Xue Za Zhi 35:529-534, 2006
  pubmed

• 10) Chiarle R, Voena C, Ambrogio C, et al.:The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23, 2008
  pubmed

• 11) Chiarle R, Simmons WJ, Cai H, et al.:Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11:623-629, 2005
  pubmed

• 12) Chiarle R, Martinengo C, Mastini C, et al.:The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 14:676-680, 2008
  pubmed

P.227 掲載の参考文献

• 1) Iuchi K, Ichimiya A, Akashi A, et al.:non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer 60:1771-1775, 1987
  pubmed

• 2) Aozasa K:Pyothorax-associated lymphoma. J Clin Exp Hematop 46:5-10, 2006
  pubmed

• 3) Narimatsu H, Ota Y, Kami M, et al.:Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol 18:22-128, 2007
  pubmed

• 4) Petitjean B, Jardin F, Joly B, et al.:Pyothorax-associated lymphoma:a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B-and T-cell phenotype. Am J Surg Pathol 26:724-732, 2002

• 5) Hongyo T, Kurooka M, Taniguchi E, et al.:Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma. Cancer. Res 58:1105-1107, 1998
  pubmed

• 6) Nishiu M, Tomita Y, Nakatsuka S, et al.:Distinct pattern of gene expression in pyothorax-associated lymphoma (PAL), a lymphoma developing in long-standing inflammation. Cancer Sci 95:828-834, 2004

• 7) Cheuk W, Chan AC, Chan JK, et al.:Metallic implant-associated lymphoma:a distinct subgroup of large B-cell lymphoma related to pyothorax-associated lymphoma? Am J Surg Pathol 29:832-836, 2005

P.233 掲載の参考文献

• 1) Matolcsy A, Chadurn A, Knowles DM:De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 147:207-215, 1995

• 2) Yamaguchi M, Seto M, Okamoto M, et al.:De novo CD5+ diffuse large B-cell lymphoma:a clinicopathologic study of 109 patients. Blood 99:815-821, 2002
  pubmed

• 3) Yamaguchi M, Nakamura N, Suzuki R, et al.:De novo CD5+ diffuse large B-cell lymphoma:Results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195-1202, 2008
  pubmed

• 4) Ennishi D, Takeuchi K, Yokoyama M, et al.:CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituxi-mab plus CHOP therapy. Ann Oncol 19:1921-1926, 2008

• 5) Ogawa S, Yamaguchi M, Oka K, et al.:CD21S antigen expression in tumor cells of diffuse large B-cell lymphoma is an independent prognostic factor indicating better oveall survival. Br J Hematol 125:180-186, 2004

• 6) Maeshima AM, Taniguchi H, Nomoto J, et al.:Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome). Am J Clin Pathol 131:339-346, 2009

• 7) Katzenberger T, Lohr A, Schwarz S, et al.:Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+progenitor B cell. Blood 101:699-702, 2003

• 8) Ybshioka T, Miura I, Kume M, et al.:Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma:Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Genes Chromosomes Cancer 42:149-157, 2005

• 9) Kobayashi T, Yamaguchi M, Kim S, et al.:Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5-diffuse large B-cell lymphomas. Cancer. Res 63:60-66, 2003

• 10) Suguro M, Tagawa H, Kagami Y, et al.:Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup:Development of a CD5 signature. Cancer Sci 97:868-874, 2006
  pubmed

• 11) Yamaguchi M, Ohno T, Oka K, et al.:De novo CD5-positive diffuse large B-cell lymphoma:clinical characteristics and therapeutic outcome. Br J Haematol 105:1133-1139, 1999
  pubmed

• 12) Linderoth J, Jerkeman M, Cavallin-Stahl E, et al.:Immunohistochemical Expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma:A Nordic Lymphoma Group Study Clin Cancer Res 9:722-728, 2003

• 13) Johnson NA, Boyle M, Bashashati A, et al.:Diffuse large B-cell lymphoma:reduced CD20 expression is associated with an inferior survival. Blood 113:3773-3780, 2009
  pubmed

• 14) Murase T, Yamaguchi M, Suzuki R, et al.:Intravascular large B-cell lymphoma (IVLBCL):a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 1O9:478-485, 2007

P.242 掲載の参考文献

• 1) De Wolf-Peeters C, Delabie J, Campo E, et al.:T cell-/histiocyte-rich large B-cell lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp238-239

• 2) Ramsay AD, Smith WJ, Isaacson PG:T cell-rich B-cell lymphoma. Am J Surg Pathol 12:433-443, 1988

• 3) Delabie J, Vandenberghe E, Kennes C, et al.:Histiocyte-rich large B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 16:37-48, 1992

• 4) Franke S, Wlodarska I, Maes B, et al.:Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol 161:1861-1867, 2002

• 5) Monti S, Savage KJ, Kutok JL, et al.:Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861, 2005
  pubmed

• 6) Meijer CJLM, Vergier B, Duncan LM, et al.:Primary cutaneous DLBCL, leg type. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, p242

• 7) Yamamoto Y, Nakamine H, Nakamura S:Recurrent primary cutaneous large B-cell lymphoma after a long-term remission. Pathol Int 56:645-647, 2006

• 8) Burg G, Jaffe ES, Willemze R, et al.:Cutaneous diffuse large B-cell lymphoma. In:WHO Classification of Tumours. Pathology and Genetics of Skin Tumours, ed by LeBoit PE, Burg G, Weedron D, et al., IARC Press, Lyon, 2006, pp198-199

• 9) Willemze R, Swerdlow SH, Harris NL, et al.:Primary cutaneous follicle centre lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp227-228

• 10) Pittaluga S, Wilson WH, Jaffe ES:Lymphomatoid granulomatosis. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp247-249

• 11) Wilson WH, Kingma DW Raffeld M, et al.:Association of lym-phomatoid granulomatosis with Epstein Barr virus infection of Blymphocytes and response to interferon-alpha 2b. Blood 87:4531-4537, 1996

• 12) Stein H, Harris NL, Campo E:Plasmablastic lymphoma. In:WHO Classification Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IA. RC Press, Lyon, 2008, pp256-257

• 13) Colomo L, Loong E Rives S, et al.:Diffuse large B-cell lym-phomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg. Pathol 28:736-747, 2004

• 14) Isaacson PG, Campo E, Harris NL:Large B-cell lymphomas arising in HHV8-associated multicentric Castleman disease. In:WHO Classification of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp258-259

• 15) Jarviluoma A, Koopal S, Rasanen S, et al.:KSHV viral cyclin binds to p27KIP in primary effusion lymphomas. Blood 104:3349-3354, 2004

• 16) Du MQ, Liu H, Diss TC, et al.:Kaposi sarcoma-assoc iated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoprolif-erative disorders. Blood 97:2130-2136, 2001

• 17) Chadburn A, Hyjek EM, Tam W, et al.:Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV;HHV-8)-infected B cells in HIV+multicentric Castleman disease (MCD). Histopathology 53:513-524, 2008
  pubmed

• 18) Said J, Cesarman E:Primary effusion lymphoma. In:WHO Classification of Tumours Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp260-261

• 19) Hollingsworth HC, Stetler-Stevenson M, Gagneten D, et al.:Immunodeficiency-associated malignant lymphoma. Three cases showing genotypic evidence of both T-and B-cell lineages. Am J Surg Pathol 18:1092-1101, 1994

• 20) Klein U, Gloghini A, Gaidano G, et al.:Gene expression pro-file analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101:4115-4121, 2003

• i) WHO Classification of Tumours Of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008

P.250 掲載の参考文献

• 1) Magrath IT:African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 13:222-246, 1991
  pubmed

• 2) Hecht JL, Aster JC:Molecular biology of Burkitt's lymphoma. J Clin Oncol 18:3707-3721, 2000
  pubmed

• 3) Hummel M, Bentink S, Berger H, et al.:Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430, 2006
  pubmed

• 4) Dave SS, Fu K, Wright GW et al.:Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 354:2431-2442, 2006
  pubmed

• 5) Nakamura N, Nakamine H, Tamaru J, et al.:The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. Mod Pathol 15:771-776, 2002

• 6) Kanungo A, Medeiros LJ, Abruzzo LV, et al.:Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 19:25-33, 2006

• 7) Niitsu N, Okamoto M, Miura I, et al.:Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t (14;18) and 8q24/c-MYC translocations. Leukemia 23:777-783, 2009

• 8) Kikuchi A, Nakamura N, Kuze T, et al.:Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes. Leuk Res 32:1176-1182, 2008
  pubmed

P.260 掲載の参考文献

• 1) 中村直哉:16. バーキットリンパ腫/白血病. 最新・悪性リンパ腫アトラス, 菊池昌弘, 森茂郎編, 文光堂, 東京, 2004, pp190-196

• 2) Blum KA, Lozanski G, Byrd C:Adult Burkitt leukemia and lymphoma. Blood 104:3009-3020, 2004

• 3) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997

• 4) Lymphoma Study Group of Japanese Pathologists:The World Health Organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000

• 5) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 6) Bellan C, Lazzi S, Hummel M, et al.:Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-p ositive and EBV-negative Burkitt lymphomas. Blood 106:1031-1036, 2005

• 7) Hochberg D, Middeldorp JM, Catalina M, et al.:Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101:239-244, 2004
  pubmed

• 8) Kian TC, Miriam T, Richard Q, et al.:Clinical characteris tics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk Lymphoma 49:824-827, 2008

• 9) Murphy SB:Classification, staging and results of treatment of childhood non-Hodgkin's lymphomas:dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980
  pubmed

• 10) Magrath I, Adde M, Shad A, et al.:Adults and children with small non-cleaved-cell lymphoma have a similar excellent outocome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996

• 11) Mead GM, Sydes MR, Walewski J, et al.:An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma:results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274, 2002
  pubmed

• 12) Freidberg JW, Ciminello L, Kelly J, et al.:Outcome of patients >age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapeutic regimens:results from the international Burkitt lymphoma cooperative group (abstr). Blood 106:#928, 2005

• 13) Thomas DA, Cortes J, O'Brien S, et al.:Hyper-CVAD program in Burkitt's type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470, 1999

• 14) Thomas DA, Faderl S, O'Brien S, et al.:Chemoimmunotherapy with hyper-CVAD plus rituxumab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006
  pubmed

• 15) Sweetenham JW Pearce R, Taghipour G, et al.:Adult Burkitt's and Burkitt like non-Hodgkin's lymphoma-Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or relapse:Results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14:2465-2472, 1996

• 16) Sweetenham JW, Proctor SJ, Blaise D, et al.:High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma:the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation. Ann Oncol 5 (suppl 2):155-159, 1994

• 17) Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.:An EBMT registry matched study of allogeneic stem cell transplant s for lymphoma:allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003
  pubmed

• 18) Cortes J, Thomas D, Rios A, et al.:Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94:1492-1499, 2002
  pubmed

• 19) Kaplan LD, Lee JY, Ambinder RE et al.:Rituximab does not improve clinical outcome in randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-as sociated non Hodgkin lymphoma:AIDS-Malignancies Consortium Trial 010. Blood 106:1538-1543, 2005

• 20) Dunleavy K, Little RE Pittaluga S, et al.:A prospective study of dose-adjusted EPOCH with rituximab in adult with newly diagnosed Burkitt lymphoma:a regimen with high efficacy and low toxicity. Ann Oncol 19 (suppl 4):iv83, 2008

• 21) Leoncini L, Raphael M, Stein H, et al.:Burkitt Lymphoma. In:WHO Classification Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC press, Lyon, 2008, pp262-264

• 22) Bociek RG:Adult Burkitt's lymphoma. Clin Lymphoma 6:11-20, 2005
  pubmed

• Perkins AS, Friedberg JW:Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program:341-348, 2008
  pubmed

• i) Kluin PM, Harris NL, Stein H, et al.:B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC press, Lyon, 2008, pp265-266

P.265 掲載の参考文献

• 1) Zucca E:Extranodal lymphoma:a reappraisal. Ann Oncol 19 (suppl 4):iv77-iv80, 2008

• 2) 岡本昌隆,新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 3) Zucca E, Conconi A, Cavalli F:Treatment of extranodal lymphomas. Best Pract Res Clin. Haematol 15:533-547, 2002
  pubmed

• 4) Shenkier TN, Connoers JM:Primary extranodal non-Hodgkin's lymphomas. In:The Lymphomas, 2nd ed, ed by Canellos GP, Lister TA, Young B, Saunders, Philadelphia, 2006, pp325-347

• 5) Zucca E, Conconi A, Pedrinis E, et al., International Extranodal Lymphoma Study Group:Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101:2489-2495, 200

• 6) Cortelazzo S, Rossi A, Oldani E, et al., International Extranodal Lymphoma Study Group (IELSG):The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Hematol 1181218-228, 2002

• 7) Cortelazzo S, Rossi A, Roggero E et al.:Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 10:1433-1440, 1999

• 8) Ryan G, Martinelli G, Kuper-Hommel M, et al., International Extranodal Lymphoma Study Group:Primary diffuse large B-cell lymphoma of the breast:prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19:233-241, 2008

• 9) Zucca E, Conconi A, Mughal TI, et al., International Extranodal Lymphoma Study Group:Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21:20-27, 2003

• 10) Ferreri AJ, Batchelor T, zucca E, et al., International Collaborative Group against Primary CNS Lymphomas. J Clin Oncol 21:1649-1650, 2003

• i) Ferry JA:Extranodal lymphoma. Arch Pathol Lab Med 132:565-578, 2008
  pubmed

P.273 掲載の参考文献

• 1) Isaacson PG, Chott A, Nakamura S, et al.:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In:WHO Classification of Tumours of Haematoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp214-217

• 2) Remstein ED, Dogan A, Einerson RR, et al.:The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 30:1546-1553, 2006
  pubmed

• 3) Streubel B, Huber D, Wohrer S, et al.:Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lym-phoid tissue lymphoma in patients with Sjogren's syndrome. Clin Cancer Res 10:476-480, 2004

• 4) Nathwani BN, Anderson JR, Armitage JO, et al.:Marginal zone B-cell lymphoma:A clinical comparison of nodal and mucosa-associated lymphoid tissue types. non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 17:2486-2492, 1999
  pubmed

• 5) Traverse-Glehen A, Felman P, Callet-Bauchu E, et al.:A clinicopathologic study of nodal marginal zone B-cell lymphoma A report of 21 cases. Histopathology 48:162-173, 2006
  pubmed

• 6) Wbtherspoon A, Chott A, Gascoyne RD, et al.:Lymphoma of the stomach. In:World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, ed by Hamilton SR, Aaltonen LA, LARC Press, Lyon, 2000, pp57-61

• 7) Zamboni G, Franzin G, Scarpa A, et al.:Carcinoma-like signet-ring cells in gastric mucosa-associated lymphoid tissue (MAIT) lymphoma. Am J Surg Pathol 20:588-598, 1996

• 8) Gascoyne RD, Muller-Hermelink HK, Chott A, et al.:B-cell lymphoma of the small intestine. In:WHO Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, ed by Hamilton SR, Aaltonen LA, IARC Press, Lyon, 2000, pp83-86

• 9) Muller-Hermelink HK, Chott A, Gascovne RD, et al.:B-cell lymphoma of the colon and rectum. In:WHO Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, ed by Hamilton SR, Aaltonen LA, IARC Press, Lyon, 2000, pp139-141

• 10) Coupland SE, Klause L, Delecluse HJ, et al.:Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Opthalmology 105:1430-1441, 1998

• 11) Chan ALC, Chan JKC, Abbondanzo SL:Haematolymphoid tumours. In:WHO Classification of Tumours. Pathology and Genetics of Head an Neck Tumours, ed by Barnes L, Eveson JW, Reichart PA, et al., IARC Press, Lyon, 2005, pp277-280

• 12) Abbondanzo S, Aozasa K, Boerner S, et al.:Primary lymphoma and plasmacytoma. In:WHO Classification of Tumours. Pathology and Genetics of Tumours Endocrine Organs, ed by DeLellis RA, Lloyd RV, Heitz PU, et al., IARC Press, Lyon, 2004, pp109-111

• 13) Hsi ED, Singleton TB Svoboda SM, et al.:Characterization of the lymphoid infiltrate in Hashimoto thyroiditis by immunohistochemistry and polymerase chain reaction for immunoglobulin heavy chain gene rearrangement. Am J Pathol 110:327-333, 1998

• 14) Nicholson AG, Harris NL:Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MAIT) type. In:WHO Classification of Tumours. Pathology and Genetics Of Tumours Lung, Pleura, Thymus, and Heart, ed by Travis WD, Brambilla E, Muller-Hermelink HK, et al, IARC Press, Lyon, 2004, pp88-90

• 15) Kempf W, Ralfkiaer E, Duncan L, et al.:Cutaneous marginal zone B-cell lymphoma. In:WHO Classification of Tumours. Pathology and Genetics. Skin Tumours, ed by LeBoit PE, Burg G, Weedon D, et al., IARC Press, Lyon, 2006, pp194-195

• 16) Harris NL, Isaacson PG, Grogan TM, et al.:Heavy chain diseases. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp196-199

P.281 掲載の参考文献

• 1) Dawson IM, Cornes JS, Morson BC:Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing Prognosis. Br J Surg 49:80-89, 1961
  pubmed

• 2) Rohatiner A, d'Amore E Coiffier B, et al.:Report on a work-shop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5:397-400, 1994

• 3) Mendelson RM, Fermoyle S:Primary gastrointestinal lymphomas:a radiological-pathological review. Part 1:Stomach, oesophagus and colon. Australas Radiol 49:353-364, 2005
  pubmed

• 4) Inagaki H, Nakamura T, Li C, et al.:Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 28:1560-1567, 2004
  pubmed

• 5) Baens M, Maes B, Steyls A, et al.:The product of the t (11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 156:1433-1439, 2000

• 6) Schechter NR, Portlock CS, Yahalom J:Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16:1916-1921, 1998
  pubmed

• 7) Ruskone-Fourmestraux A, Delmer A, et al.:Gastro-intestinal lymphomas. Gastroenterol Clin Biol 2:2S81-2S90, 2006

• 8) Levy M, Copie-Bergman C, Gameiro C, et al.:Prognostic value of translocation t (11;18) in tumoral response of lowgrade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 23:5061-5066, 2005
  pubmed

• 9) Psyrri A, Papageorgiou S, Economopoulos T:Primary extranodal lymphomas of stomach:clinical presentation, diagnostic pitfalls and management. Ann Oncol 19:1992-1999, 2008

• 10) Martinelli G, Laszlo D, Ferreri AJ, et al.:Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23:1979-1983, 2005
  pubmed

• 11) Dickson BC, Serra S, Chetty R:Primary gastrointes tinal tractlymphoma:diagnosis and management of common neoplasms. Expert Rev Anticancer Ther 6:1609-1628, 2006

• 12) Wohrer S, Puspok A, Drach J, et al.:Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol 15:1086-1090, 2004
  pubmed

• 13) Ishikura S, Tobinai K, Ohtsu A, et al.:Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci 96:349-352, 2005

• 14) Wong MT, Eu KW:Primary colorectal lymphomas. Colorectal Dis 8:586-591, 2006
  pubmed

• 15) Cho MJ, Ha CS, Allen PK, et al.:Primary non-Hodgkin lymphoma of the large bowel. Radiology 205:535-539, 1997
  pubmed

• 16) Tsang RW Gospodarowicz MK, Pintilie M, et al.:Stage I and II MAIT lymphoma:results of treatment with radiotherapy Int J Radiat Oncol Biol Phys 50:1258-1264, 2001

• i) Psyrri A, Papageorgiou S, Economopoulos T:Primary extranodal lymphomas of stomach:clinical presentation, diagnostic pitfalls and management. Ann Oncol 19:1992-1999, 2008

P.285 掲載の参考文献

• 1) Freeman C, Berg JW Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260, 1972
  pubmed

• 2) Derringer GA, Thompson LD, Frommelt RA, et al.:Malignant lymphoma of the thyroid gland:a clinicopathologic study of 108 cases. Am J Surg Pathol 24:623-639, 2000
  pubmed

• 3) Widder S, Pasieka JL:Primary thyroid lymphomas. Curr Treat Options Oncol 5:307-313, 2004
  pubmed

• 4) Niitsu N, Okamoto M, Nakamura N, et al.:Clinicopathologic correlations of stage I E/II E primary thyroid diffuse large B-cell lymphoma. Ann Oncol 18:1203-1208, 2007

• 5) Hans CR Weisenburger DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103:275-282, 2004

• 6) Sato Y, Nakamura N, Nakamura S, et al.:Deviated VH4 immunoglobulin gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at o ther sites, but is not found in thyroid diffuse large B-cell lymphomas. Mod Pathol 19:1578-1584, 2006

• 7) DiBiase SJ, Grigsby PW, Guo C, et al.:Outcome analysis for stage I E and II E thyroid lymphoma. Am J Clin Oncol 27:178-184, 2004

• 8) Niitsu N, Okamoto M, Aoki S, et al.:Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleo-mycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol 85:374-380, 2006

• i) Harrington KJ, Michalaki VJ, Vini L, et al.:Management of non-Hodgkin's lymphoma of the thyroid:the Royal Marsden Hospital experience. Br J Radiol 78:405-410, 2005

P.290 掲載の参考文献

• 1) Shenkier TN, Connoers JM:Primary extradonal non-Hodgkin's lymphomas. In:The Lymphomas, 2nd ed, ed by canellos GP, Lister TA, Young B, Saunders, Philadelphia, 2006, pp325-347.

• 2) Coupland SE, Krause L, Delecluse HJ, et al.:Lymphoproliferative lesions of the ocular adnexa:analysis of 112 cases. Ophthalmology 105:1430-1441, 1998
  pubmed

• 3) Tanimoto K, Kaneko A, Suzuki S, et al.:Primary ocular adnexal MALT lymphoma:along-term follow-up study of 114 patients. Jpn J Clin Oncol 37:337-344, 2007

• 4) Ferry JA, Fung CY, Zukerberg L, et al.:Lymphoma of the ocular adnexa:A study of 353 cases. Am J Surg Pathol 31:170-184, 2007
  pubmed

• 5) Lagoo AS, Haggerty C, Kim Y, et al.:Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classification:are marginal zone lymphomas in the orbit mucosa-associated lymphoid tissue-type lymphomas?Arch Pathol Lab Med 132:1405-1416, 2008

• 6) Remstein ED, Dogan A, Einerson RR, et al.:The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 30:1546-1553, 2006
  pubmed

• 7) Streubel B, Huber D, Wohrer S, et al.:Frequency of chromosomal aberrations involving MALTI in mucosa-associated lymphoid tissue lymphoma in patients with Sjogren's syndrome. Clin Cancer Res 10:476-480, 2004

• 8) Tanimoto K, Sekiguchi N, Yokota Y, et al.:Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer 6:249, 2006
  pubmed

• 9) Ferreri AJ, Guidoboni M, Ponzoni M, et al.:Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96:586-594, 2004
  pubmed

• 10) Chanudet E, Zhou Y, Bacon CM, et al.:Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol 209:344-351, 2006
  pubmed

• 11) Decaudin D, Dendale R, Lumbroso-Le Rouic L:Treatment of mucosa-associated lymphoid tissue-type ocular adnexal lymphoma. Anticancer Drugs 19:673-680, 2008

• 12) Isobe K, Kagami Y, Higuchi K, et al.:A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas:apreliminary report from the Japan Radiation Oncology Group OAROG). Int J Radiat Oncol Biol Phys 69:1181-1186, 2007

• 13) Bessell EM, Henk JM, Wright JE, et al.:Orbital and conjunctival lymphoma treatment and prognosis. Radiother Oncol 13:237-244, 1988
  pubmed

• 14) Esmaeli B, McLaughlin P, Pro B, et al.:Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20:709-714, 2009
  pubmed

• 15) Matsuo T, Yoshino T:Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma. Ophthalmology 111:1233-1237, 2004
  pubmed

• i) Sato Y, Ohshima K, Ichimura K, et al.:Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int 8:465-470, 2008
  pubmed

P.294 掲載の参考文献

• 1) Wiseman C, Liao KT:Primary lymphoma of the breast. Cancer 29:1705-1712, 1972
  pubmed

• 2) Lopez-Guillermo A, Colomo L, Jimenez M, et al.:Diffuse large B-cell lymphoma:clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 23:2797-2804, 2005
  pubmed

• 3) Niitsu N, Okamoto M, Nakamine H, et al.:Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma. Leule Res 32:1837-1841, 2008
  pubmed

• 4) Ryan G, Martinelli G, Kuper-Hommel M, et al.:Primary diffuse large B-cell lymphoma of the breast:prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19:233-241, 2008

• 5) Leoncini L, Raphael M, Stein H, et al.:Burkitt lympoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp262-264

• 6) Yoshida S, Nakamura N, Sasaki Y, et al.:Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 18:398-405, 2005

• 7) Fruchart C, Denoux Y, Chasle J, et al.:High grade primary breast lymphoma:is it a different clinical entity?Breast Cancer Res Treat 93:191-198, 2005
  pubmed

• 8) Ganjoo K, Advani R, Mariappan MR, et al.:Non-Hodgkin lymphoma of the breast. Cancer 110:25-30, 2007
  pubmed

• 9) Aviles A, Castafieda C, Neri N, et al.:Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica 92:1147-1148, 2007

• 10) Wong WW, Schild SE, Halyard MY, et al.:Primary non-Hodgin lymphoma of the breast:The Mayo Clinic experience. J Surg Oncol 80:19-25, 2002

• 11) Au WY, Chan AC, Chow LW et al.:Lymphoma of the breast in Hong Kong Chinese. Hematol Oncol 15:33-38, 1997

• 12) Validire P, Capovilla M, Asselain B, et al.:Primary breast non-Hodgkin's lymphoma:a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol 84:133-139, 2009
  pubmed

P.297 掲載の参考文献

• 1) Zucca E, Conconi A, Mughal TI, et al.:Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21:20-27, 2003

• 2) Marx A, Woodward PJ:Lymphoma and plasmacytoma of the testis and paratesticular tissues. In:World Health Organization Classification of Tumours. Pathology and Genetics of the Urina ry Sγstem and Male Genital Organs, ed by Eble JN, Sauter G, Epstein JE, et al., IARC Press, Lyon, 2004, pp263-264

• 3) Mazzu D, Jeffrey RB Jr, Ralls PW:Lymphoma and leukemia involving the testicles:findings on gray-scale and color dop-pler sonography AIR Am J Roentgenol 164:645-647, 1995

• 4) Bacon CM, Ye H, Diss TC, et al.:Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 31:1050-1058, 2007
  pubmed

• 5) Pileri SA, Sabattini E, Rosite P, et al.:Primary follicular lymphoma of the testis in childhood:an entity with peculiar clinical and molecular characteristics. J Clin Pathol 55:684-688, 2002

• 6) Al-Abbadi MA, Hattab EM, Tarawneh MS, et al.:Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup:A study of 18 cases. Mod Pathol 19:1521-1527, 2006

• 7) Vitolo U, Zucca E, Chiappella A, et al.:Primary diffuse large B-cell lymphoma of the testis improved outcome with rituximab-CHOP with CNS and contralateral testis prophylaxis. final results of IELSG 10 Study. Haematologica 93:abstract#401, 2008

P.304 掲載の参考文献

• 1) Desai S, Jambhekar NA, Soman CS, et al.:Primary lymphoma of bone:a clinicopathologic study of 25 cases reported over 10 years. J Surg Oncol 46:265-269, 1991

• 2) Mulligan ME, McRac GA, Murphey MD:Imaging features of primary lymphoma of bone. AJR Am J Roentgenol 173:1691-1697, 1999

• 3) Unni KK, Hogendoorn PCW:Malignant lymphoma. In:World Health Organization Classification of Tumours. Pathology and Genetics of Tumours Of Soft Tissue and Bone, ed by Fletcher CD, Unni KK, Mertens E Lyon, pp306-308, 2002

• 4) Vincent JM, Ng YY, Norton AJ, et al.:Case report:Primary lymphoma of bone-MR Imaging appearances with pathological correlation. Clin Radiol 45:407-409, 1992

• 5) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 6) Durr HR, Muller PE, Hiller E, et al.:Malignant lymphoma of bone. Arch Orthop Trauma Surg 122:10-16, 2002
  pubmed

• 7) Gianelli U, Patriarca C, Moro A, et al.:Lymphomas of the bone:A pathological and clinical study of 54 cases. Int J Surg Pathol 10:257-266, 2002

• 8) Marshall DT, Amdur RJ, Scarborough MT, et al.:Stage I E pri-mary non-Hodgkin's lymphoma of bone. Clin Orthop 405:216-222, 2002

• 9) Zinzani PL, Carrillo G, Ascani S, et al.:Primary bone lymphoma:experience with 52 patients. Haematologica 88:280-285, 2003
  pubmed

• 10) Krishnan A, Shirkhoda A, Tehranzadeh J, et al.:Primary Bone Lymphoma:Radiographic-MR imaging correlation. Radiographics 23:1371-1383, 2003
  pubmed

• 11) Ozdemirli M, Mankin HJ, Aisenberg AC, et al.:Hodgkin's disease presenting as a solitary bone tumor. A report of four cases and review of the literature. Cancer 77:79-88, 1996
  pubmed

• 12) Heyning FH, Hogendoorn PC, Kramer MH, et al.:Primary non-Hodgkin's lymphoma of bone:aclinicopathological inves-tigation of 60 cases. Leukemia 12:2094-2098, 1999

• 13) Ueda T, Aozasa K, Ohsawa M, et al.:Malignant lymphomas of bone in Japan. Cancer 64:2387-2392, 1989
  pubmed

• 14) Ostrowski ML, Inward CY, Strickler JG, et al.:Osseous Hodg-kin disease. Cancer 85:1166-1178, 1999

• 15) Chan JK, Ng CS, Hui PK, et al.:Anaplastic large cell Ki-1 lymphoma of bone. Cancer 68:2186-2191, 1991
  pubmed

• 16) Misgeld E, Wehmeier A, Kromeke O, et al.:Primary non-Hodgkin's lymphoma of bone:three cases and a short review of the literature. Ann Hematol 82:440-443, 2003

• 17) Heyning FH, Hogendoorn PC, Kramer MH, et al.:Primary non-Hodgkin's lymphoma of bone:a clinicopathological investigation of 60 cases. Leukemia 13:2094-2098, 1999

• 18) Remadan MK, Shenkier T, Sehn LH, et al.:A clinicopathological retrospective study of 131 patients with primary bone lymphoma:a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Ann Oncol 18:129-135, 2007

P.310 掲載の参考文献

• 1) Isaacson PG, Norton AJ:Extranodal lymphomas, Churchill Livingstone, New York, 1994

• 2) Freeman C, Berg JW Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260, 1972
  pubmed

• 3) Ferraro P, Trastek VE Adlakha H, et al.:Primary non-Hodgkin's lymphoma of the lung. Ann Thorac Surg 69:993-997, 2000

• 4) 岡本昌隆, 新津望, 三浦偉久男ほか:2000 例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 5) Zinzani PL, Tani M, Gabriele A, et al.:Extranodal marginal zone B-cell lymphoma of MALT-type of the lung:Single center experience with 12 patients. Leule Lymphoma 44:821-824, 2003
  pubmed

• 6) Wannesson L, Cavalli E Zucca E:Primary pulmonary lymphoma:current status. Clin Lymphoma Myeloma 6:220-227, 2005

• 7) King LJ, Padley SP, Wotherspoon AC, et al.:Pulmonary MALT lymphoma:imaging findings in 24 cases. Eur Radiol 10:1932-1938, 2000
  pubmed

• 8) Cadranel J, Wislez M, Antoine M:Primary pulmonary lymphoma. Eur Respir J 20:750-762, 2002
  pubmed

• 9) Kostakoglu L, Coleman M, Leonard JP, et al.:PET predict s prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
  pubmed

• 10) 稲垣宏, 岡部光邦:肺のリンパ腫各論/2. 臓器別リンパ腫の特徴 悪性リンパ腫のすべて. 血液・腫瘍科49 (suppl 4):665-671, 2004

• 11) Akagi T, Motegi M, Tamur A, et al.:A novel gene, MALT1 at 18q21, is involved in t (11;18) (q21;q21) found in low-g rade B-cell lymphoma of mucosa-associated lymphoid tissue. Onco-gene 18:5785-5794, 1999

• 12) Ye H, Liu H, Attygalle A, et al.:Variable frequencies of t(11;18) (q21;q21) in MALT lymphomas of different sites:significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 102:1012-1018, 2003
  pubmed

• 13) Rosenwald A, Ott G, Stilgenbauer S, et al.:Exclusive detection of the t (11:18) (q21;q21) in extranodal marginal zone B cell lymphoma (MZBL) of MALT type in contrast of other MZBL and extranodal large B cell lymphomas. Am J Pathol 155:1817-1821, 1999

• 14) Zucca E, Conconi A, Pedrinis E, et al.:Nongastric mar ginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101:2489-2495, 2003

• 15) Coldier JE Chailleux E, Lauque D, et al.:Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompro-mised patients. Chest 103:201-208, 1993

• 16) Conconi A, Martinelli G, Thieblemont C, et al.:Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102:2741-2745, 2003
  pubmed

• 17) Jager G, Neumeister P, Brezinschek R, et al.:Treatment of extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue type with cladribine:a phase II study. J Clin Oncol 20:3872-3877, 2002
  pubmed

P.314 掲載の参考文献

• 1) Ferry JA, Young RH:Malignant lymphoma, pseudolymphoma, and hematopoietic disorders of the female genital tract. Pathol Annu 26:227-263, 1991
  pubmed

• 2) Freeman C, Berg JW, Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260, 1972
  pubmed

• 3) Chorlton I, Norris HJ, King FM:Malignant reticuloendothelial disease involving the ovary as a primary manifestation:a series of 19 lymphomas and 1 granulocytic sarcoma. Cancer 34:397-407, 1974

• 4) 岡本昌隆,新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 5) Isaacson PG, Norton AJ:Malignant lymphoma of the urogenital tract. In:Extranodal lymphomas, ed by Isaacson PG, Norton AJ, Churchill Livingstone, Edinburgh, 1994, pp273-287

• 6) Rotmensch J, Woodruff JD:Lymphoma of the ovary:report of twenty new cases and update of previous series. Am J Obstet Gynecol 143:870-875, 1982
  pubmed

• 7) Andrews SJ, Hernandez E, Woods J, et al.:Burkitt's-like lymphoma presenting as a gynecologic tumor. Gynecol Oncol 30:131-136, 1988

• 8) Harris NL, Scully RE:Malignant lymphoma and granulocytic sarcoma of the uterus and vagina. a clinicopathologic analysis of 27 cases. Cancer 53:2530-2545, 1984

• 9) Osborn BM, Robboy SJ:Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases. Cancer 52:1933-1943, 1983
  pubmed

• 10) Chorlton I:Malignant lymphoma of the female genital tract and ovaries. In:Haines and Taylor obstetrical and gynaecological pathology, ed by Fox H, Churchill Livingstone, Edinburgh, 1987, p737

• 11) Jaffe ES:Surgical Pathology of the lymph nodes and related organs, W B. Saunders, Philadelphia, 1985

• 12) Dimopoulos MA, Dariani D, Pugh W, et al.:Primary ovarian non-Hodgkin's lymphoma:Outcome after treatment with combination chemotherapy Gyneco Oncol 64:446-450, 1997

• 13) Lopez TM, Hagemeister FB, McLaughlin B et al.:Small noncleaved cell lymphoma in adults:superior results for stage I-III disease. J Clin Oncol 8:615-622, 1990

• 14) Vang R, Medeiros LJ, Warnke RA, et al.:Ovarian non-Hodgkin's lymphoma:aclinicopathologic study of eight pri-mary cases. Mod Pathol 14:1093-1099, 2001

• 15) Chorlton I, Karnei RE King FM, et al.:Primary malignant reticuloendotherial disease involving the vagina cervix and cor-pus uteri. Obstet Gynecol 44:735-748, 1974

• 16) Khoury GG, Robinson A:Lymphoma of uterine cervix. Eur J Surg Oncol 15:65-67, 1989
  pubmed

P.317 掲載の参考文献

• 1) Vega F Lin P, Medeiros LJ:Extranodal lymphomas of the head and neck. Ann Diagn Pathol 9:340-350, 2005
  pubmed

• 2) Cuadra-Garcia I, Prouly GM, Wu CL, et al.:Sinonasal lympho-ma:aclinicopathologic analysis of 58 cases from the Massa-chusetts General Hospital. Am J Surg Pathol 23:1356-1369, 1999

• 3) Cheung MM, Chan JK, Lau WH, et al.:Primary non-Hodgkin's lymphoma of the nose and nasopharynx:clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998
  pubmed

• 4) Hill QA, Owen RG:CNS prophylaxis in lymphoma:WHO Classification to target and what therapy to use. Blood Reviews 20:319-332, 2006

• 5) Kim GE, Koom WS, Yang WI, et al.:Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck 26:584-593, 2004
  pubmed

• 6) Oprea C, Cainap C, Azoulay R, et al.:Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses:a report of 14 cases. Br J Haematol 131:468-471, 2005

P.322 掲載の参考文献

• 1) d'Amore E Brincker H, Christensen BE, et al.:Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol 3:379-386, 1992

• 2) Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients:The non-Hodgkin's Lymphoma Classification Prolect. Ann Oncol 8:973-978, 1997

• 3) Thieblemont C, Coiffier B:Lymphoma in older patients. J Clin Oncol 25:1916-1923, 2007
  pubmed

• 4) Van Zant G, Liang Y:The role of stem cells in aging. Exp Hematol 31:659-672, 2003
  pubmed

• 5) Mori M, Niitsu N, Takagi T, et al.:Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 41:359-366, 2001
  pubmed

• 6) Niitsu N, Iijima K:Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive on-Hodgkin's lymphoma in elderly patients:a prospective study Ann Hematol 80:602-606, 2001
  pubmed

• 7) Pfreundschuh M, Trumper L, Kloess M, et al.:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004

• 8) Feugier P, Van Hoof A, Sebban C, et al.:Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005

• 9) Habermann TM, Weller EA, Morrison VA, et al.:Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
  pubmed

• 10) Pfreundschuh M, Schubert J, Ziepert M, et al.:Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas arandomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
  pubmed

• 11) Boehme V, Schmitz N, Zeynalova S, et al.:CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab:An analysis of patients treated in the RICOVER-60 tri al of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). Blood 113:3896-3902, 2009
  pubmed

• 12) Feugier P, Virion JM, Tilly H, et al.:Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma:influence of rituximab. Ann Oncol 15:129-133, 2004
  pubmed

• 13) Lugtenburg PJ, Sonneveld P:Treatment of diffuse large B-cell lymphoma in the elderly:strategies integrating oncogeriatric themes. Curr Oncol Rep 10:412-419, 2008
  pubmed

P.329 掲載の参考文献

• 1) WHO Claxxification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL,et al.,IARC Press, Lyon,2008

• 2) A clinical evaluation of the International Lymphoma Stydy Group Classification non-Hodgkin's lymphoma. The NonHodgkin's Lymphoma Classification Project. Blood 89:3909-3918,1997

• 3) Vose J,Armitage J,Weisenburger D, et al.:International peripheral T-cell and natural Killer/T-cell lymphoma study:phathology findings and clinical findings. J Clin Oncol 26:4124-4130,2008

• 4) Aoki R, Karube K,Sugita Y,et al.:Distribution of malignant lymphoma in Japan : analysis of 2260 cases,2001-2006.Pathol Int 58:174-182,2008
  pubmed

P.334 掲載の参考文献

• 1) Pilozzi E, Pulford K, Jones M, et al.:Co-experssion on CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 186:140-143, 1998

• 2) Paietta E, Ferrando AA, Neuberg D, et al.:Activating FLT3 mutations in CD117/KIT+T-cell acute lymphoblastic leukemias. Blood 104:558-560, 2004

• 3) Pilozzi E, Muller-Hermelink HK, Falini B, et al.:Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 188:267-270, 1999

• 4) Okuda T, Fisher R, Downing JR:Moelecular diagnostics in pediatric acute lymphoblastic leukemia. Mol Diagn 1:139-151, 1996

• 5) Katsuno M, Abe Y, taguchi F, et al.:CD7+stem cell leukemia/lymphoma. Features of a subgroup without circulating blast cells. Cancer 72:99-104, 1993
  pubmed

• 6) Chaperot L, Bendriss N, Manches O, et al.:Identification of leukemic counterpart of the plasmacytoid dendrictic cells. Blood 97:210-3217, 2001

• 7) Suzuki R, Yamamoto K, Seto M, et al.:CD7+and CD56+myeloid/natural killer cell precursor acute leukemia:a distinct hematolymphoid disease entity. Blood 90:2417-2428, 1997
  pubmed

• 8) Chan JKC, Jaffe ES, Ralfkiaer E:Blastic NK-cell lymphoma. In:WHO classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed by Jaffe ES, Harris NL, Stein H, et al., IARC Press, Lyon, 2001, pp214-215

• 9) Petrella T, Comeau MR, Maynadie M, et al.:"Agranula CD4+ CD56+hematodermic neoplasm" (blastic NK-cell lymphoma) originates from a population of CD56+precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 26:852-862, 2002
  pubmed

• 10) Herling M, Teitell MA, Shen RR, et al.:TCL1 expression in plasmacytoid dendrictic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101:5007-5009, 2003

• 11) Herling M, Jones D:CD4+/CD56+hematodermic tumor:the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 127:687-700, 2007
  pubmed

• 12) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al.:LARC Press, Lyon, 2008

• i) Millot E Suciu S, Philippe N, et al.:Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia:Result of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 19:1935-1942, 2001

P.342 掲載の参考文献

• 1) Delsol G, Jaffe ES, Falini B, et al.:Anaplastic large cell lymphoma (ALCL), ALK-positive. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp312-316

• 2) Shiota M, Nakamura S, Ichinohasama R, et al.:Anaplastic large cell lymphomas expressing the novel chimeric protein P80NPM/ALK:a distinct clinicopathologic entity Blood 86:1954-1960, 1995
  pubmed

• 3) Nakamura S, Shiota M, Nakagawa A, et al.:Anaplastic large cell lymphoma:a distinct molecular pathologic entity:a reappraisal with special reference to p80NPM/ALK expression. Am J Surg J Pathol 21:1420-1432, 1997

• 4) Suzuki R, Kagami Y, Takeuchi K, et al.:Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993-3000, 2000
  pubmed

• 5) Mason DY, Campo E, Harris NL, et al.:Anaplastic large cell lymphoma, ALK-negative. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp317-319.

• 6) Asano N, Suzuki R, Matsuo K, et al.:Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma. Histopathology 50:705-715, 2007
  pubmed

• 7) Ralfkiaer E, Willemze R, Pauli M, et al.:Primary cutaneous CD30-positive T-cell lymphoproliferative disorders, In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp300-301

P.348 掲載の参考文献

• 1) Stein H, Mason DY, Gerdes J, et al.:The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blodd 66:848-858, 1985

• 2) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008

• 3) Savage KJ, Harris NL, Vose JM, et al.:ALK-Lanaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008

• 4) Stein H, Foss HD, Durkop H, et al.:CD30+ anaplastic large cell lymphoma:a review of its histopathologic, genetic, and clinical features. Blood 496:3681-3695, 2000

• 5) Bonzheim I, Geissinger E, Roth S, et al.:Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell reptor signaling. Blood 104:3358-3360, 2004

• 6) ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al.:ALK-negative systemic anaplastic large cell lymphoma:differential diagnostic and prognostic aspects a review. J Pathol 200:4-15, 2003
  pubmed

• 7) Falini B, Pulford K, Pucciarini A, et al.:Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 94:3509-3515, 1999
  pubmed

• 8) Fiorani C, Vinci G, Sacchi S, et al.:Primary systemic anaplastic large-cell lymphoma (CD30+):advances in biology and current therapeutic approaches. Clin Lymphoma 2:29-37, 2001
  pubmed

• 9) Suzuki R, Kagami Y, Takeuchi K, et al.:Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. . Blood 96:2993-3000, 2000
  pubmed

• 10) Falini B, Pileri S, Zinzani PL, et al.:ALK+lymphoma:clinicopathological findings and outcome. Blood 93:2697-2706, 1999
  pubmed

• 11) Gascoyne RD, Aoun P Wu D, et al.:Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913-3921, 1999
  pubmed

• 12) Tilly H, Gaulard P, Lepage E, et al.:Primary anaplastic large-cell lymphoma in adults:clinical presentation, immunophenotype, and outcome. Blood 90:3727-3734, 1997
  pubmed

• 13) Jagasia M, Morgan D, Goodman S, et al.:Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45:2261-2267, 2004
  pubmed

• 14) Fanin R, Ruiz de Elvira MC, et al.:Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma:analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 23:437-442, 1999

• 15) Deconinck E, Lamy T Foussard C, et al.:Autologous stem cell transplantation for anaplastic large-cell lymphomas:results of a prospective trial. Br J Hematol 109:736-742, 2000

• 16) Fanin R, Silvestri F, Geromin A, et al.:Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult:sequential intensive treatment with the F-MACHOP regimen (+/-radiotherapy) and autologous bone marrow transplantation. Blood 87:1243-1248, 1996

• 17) Rassidakis GZ, Goy A, Medeiros LJ, et al.:Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res 9:2213-2220, 2003
  pubmed

• 18) Schlette EJ, Medeiros LJ, Goy A, et al.:Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22:1682-1688, 2004
  pubmed

P.355 掲載の参考文献

• 1) Suchi T:Atypical hyperplasia of lymph nodes with poor prognosis:immunological characterization of the proliferating cells. Res Adv RES Res 18:124-133, 1978

• 2) Shimoyama M, Minato K, Saito H, et al.:Immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma. Jpn J Clin Oncol 9 (suppl):347-356, 1979

• 3) Dogan A, Attygalle AD, Kyriakou C:Angioimmunoblastic T-cell lymphoma. Br J Haematol 121:681-691, 2003
  pubmed

• 4) Dupuis J, Boye K, Martin N, et al.:Expression o f CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL):a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30:490-494, 2006

• 5) de Leval L, Rickman DS, Thielen C, et al.:The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952-4963, 2007
  pubmed

• 6) Jones D, Jorgensen JL, Shahsafaei A, et al.:Characteristic proliferations of reticular and dendritic cells in angioimmunooblastic lymphoma. Am J Surg. Pathol 22:956-964, 1998
  pubmed

• 7) Anagnostopoulos I, Hummel M, Finn T, et al.:Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80:1804-1812, 1992
  pubmed

• 8) Zettl A, Lee SS, Rudiger T, et al.:Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 117:368-379, 2002
  pubmed

• 9) Quintanilla-Martinez L, Fend E Moguel LR, et al.:Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol 23:1233-1240, 1999

P.361 掲載の参考文献

• 1) Dogan A, Gaulard P, Jaffe ES, et al.:Angioimmunoblastic T-cell lymphoma. In:WHO Classification of Tumours of Haemapoietic and Lynzphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL et al., IARC Press, Lyon, 2008

• 2) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 3) Mourad N, Mounier N, Briere J, et al,:Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111:4463-4470, 2008

• 4) Dogan A, Attygalle AD, Kyriakou C:Angioimmunoblastic T-cell lymphoma. Br J Haematol 121:681-691, 2003
  pubmed

• 5) Niitsu N, Okamoto M, Nakamine H, et al.:Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 26:152-158, 2008
  pubmed

• 6) Went P, Agostinelli C, Gallamini A, et al.:Marker expre ssion in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score. J Clin Oncol 24:2472-2479, 2006

• 7) Dupuis J, Boye K, Martin N, et al.:Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL):a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30:490-494, 2006
  pubmed

• 8) Dunleavy K, Wilson WH, Jaffe ES:Angioimmunoblastic T cell lymphoma:pathobiological insights and clinical implications. Curr Opin Hematol 14:348-353, 2007
  pubmed

• 9) Pangalis GA, Moran EM, Rappaport H:Blood and bone marrow findings in angioimmunoblastic lymphadenopathy Blood 51:71-83, 1978
  pubmed

• 10) Siegert W, Agthe A, Griesser H, et al.:Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study Kiel Lymphoma Study Group. Ann Intern Med 117:364-370, 1992

• 11) Sallah S, Gagnon GA:Angioimmunoblastic lymphad enopathy with dysproteinemia:emphasis on pathogenesis and treatment. Acta. Haematol 99:57-64, 1998

• 12) Pautier B Devidas A, Delmer A, et al.:Angioimmunoblastic-like T-cell non Hodgkin's lymphoma:outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 32:545-552, 1999
  pubmed

• 13) Schetelig J, Fetscher S, Reichle A, et al.:Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88:1272-1278, 2003
  pubmed

• 14) Kyriakou C, Canals C, Goldstone A, et al.:High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma:Complete Remission at Transplantation is the major determinant of Outcome Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:218-224, 2008

• 15) Rodriguez J, Conde E, Gutierrez A, et al.:Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation:the GELTAMO experience. Eur J Haematol 78:290-296, 2007
  pubmed

• 16) Advani R, Horwitz S, Zelenetz A, et al.:Angioimmunoblastic Tcell lymphoma:treatment experience with cyclosporine. Leuk Lymphoma 48:521-525, 2007
  pubmed

• 17) Siegert W, Nerl C, Meuthen I, et al.:Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy:results in 12 patients. Leukemia 5:892-895, 1991
  pubmed

• 18) Halene S, Zieske A, Berliner N:Sustained remission fr m angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol 3:165-168; quiz 169, 2006

• 19) Gallamini A, Zaja E Patti C, et al.:Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma:results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007

• 20) Bruns I, Fox E Reinecke P, et al.:Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. . Leukemia 19:1993-1995, 2005

• 21) Aguiar Bujanda D:Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 19:396-397, 2008

• 22) Siegert W, Nerl C, Agthe A, et al.:Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 6:659-664, 1995

• 23) Schlegelberger B, Zwingers T Hohenadel K, et al.:Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. J Clin Oncol 14:593-599, 1996

• 24) Iannitto E, Ferreri AJ, Minardi V, et al.:Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol 68:264-271, 2008
  pubmed

• 25) Zhao WL, Mourah S, Mounier N, et al.:Vascular endothelialgrowth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 84:1512-1519, 2004

P.362 掲載の参考文献

• i) Steeg PS, Bevilacqua G, Kopper L, et al:Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80:200, 1988
  pubmed

• ii) Niitsu N, Honma Y, Iijima K, et al:Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma. Leukemia 17:196, 2003

P.369 掲載の参考文献

• 1) Lennert K, Feller AC:Histopathology of Non-Hodgkin's Lymphoma (Based on the Updated Kiel Classification), Springer-Verlag, Berlin, 1992

• 2) Rizvi MA, Evens AM, Tallman MS, et al.:T-cell non-Hodg-kin lymphoma. Blood 107:1255-1264, 2006

• 3) Suchi T, Lennert K, Tu LY, et al.:Histopathology and immuno-histochemistry of peripheral T-cell lymphoma:a proposal for their classification. J Clin Pathol 40:995-1015, 1987

• 4) Streubel B, Vinatzer U, Willheim M, et al.:Novel t(5;9) (q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20:313-318, 2006
  pubmed

• 5) Yamashita Y, Nakamura S, Kagami Y, et al.:Lennert's lymphoma:A variant of cytotoxic T-cell lymphoma? Am J Surg Pathol 24:1627-1633, 2000

P.377 掲載の参考文献

• 1) Pileri SA, Weisenburger DD, Sng I, et al,:Peripheral T-ell lymphoma, not otherwise specified. In:WHO Classifiationof Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp306-308
  pubmed

• 2) de Leval L, Bisig B, Thielen C, et al.:Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol, 2009 (in press)

• 3) Rodriguez-Abreu D, Filho VB, Zucca E:Peripheral T-cell lymphomas, unspecified (or not otherwise specified):a review. Hematol Oncol 26:8-20, 2008
  pubmed

• 4) Niitsu N, Okamoto M, Nakamine H, et al.:Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 26:152-158, 2008
  pubmed

• 5) Vose J, Amlitage J, Weisenburger D, et al.:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
  pubmed

• 6) Rodriguez J, Gutierrez A, Martinez-Delgado B, et al.:Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit Rev Oncol Hematol, 2008 (in press)

• 7) Fisher RI, Gaynor ER, Dahlberg S, et al.:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
  pubmed

• 8) Schmitz N, Ziepert M, Nickelsen M, et al.:T-cell lymphomas in studies of the German High-Grade non-Hodgkin's Lymphoma Study Group (DSHNHL) (abstr), Ann Oncol 9 (supp 4):94a, 2008

• 9) Gressin R, Peoch M, Deconinck E, et al.:The VIP-ABVD Regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T-cell lymphoma. Final resul ts of the:'LTP95"protocol of the GOELAMS (abstr). Blood 108:2464, 2006
  pubmed

• 10) Sung HJ, Kim SJ, Seo HY, et al.:Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B:single institutional study Br J Hematol 134:45-53, 2006

• 11) Martinez-Delgado B, Cuadros M, Honrado E, et al.:Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas. Leukemia 19:2254-2263, 2005

• 12) Greer JP:Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program:331-337, 2006
  pubmed

• 13) Tilly H, Lepage E, Coiffier B, et al.:Intensive conventional (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003
  pubmed

• 14) Corradini P, Tarella C, Zallio E et al.:Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533-1538, 2006
  pubmed

• 15) Reimer P, Schertlin T, Rudiger T, et al.:Myeloablative radiohemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas:first results of a prospective multicenter study Hematol J 5:304-311, 2004

• 16) Mounier N, Gisselbrecht C, Briere J, et al.:All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation:a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 15:1790-1797, 2004
  pubmed

• 17) Gisselbrecht C, Lepage E, Molina T, et al.:Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479, 2002
  pubmed

• 18) Reimer P, Ruediger T, Weissinger F, et al.:Different outcome for angioimmunoblastic T-cell lymphoma (AIL) and peripheral T-cell lymphoma unspecified (PTCL-U) following upfront autologous stem cell transplantation (abstr). Blood 108:5431, 2006

• 19) d'Amore E Relander T, Lauritzsen G, et al.:Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL)-a phase II study of the Nordic Lymphoma Group (NLG) (abstr). Blood 108:401, 2006

• 20) Mercadal S, Briones J, Xicoy B, et al.:Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19:958-963, 2008

• 21) Rodriguez J, Conde E, Gutierrez A, et al.:Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma:a prospective study from The Gel-Tamo Study Group. Eur J Hematol 79:32-38, 2007

• 22) Reimer R Rudiger T, Geissinger E, et al.:Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas:results of a prospective multicenter study J Clin Oncol 27:106-113, 2009

• 23) Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al.:Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134:202-207, 2006

• 24) Corradini P, Dodero A, Zallio F, et al.:Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004

• 25) Le Gouill S, Milpied N, Buzyn A, et al.:Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults:a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26:2264-2271, 2008
  pubmed

• 26) Gallamini A, Stelitano C, Calvi R, et al.:Peripheral T-cell lymphoma unspecified (PTCL-U):a new prognostic model from a retrospective multicentric clinical study Blood 103:2474-2479, 2004

• 27) Savage KJ:Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program:280-288, 2008
  pubmed

• 28) Niitsu N, Nakamine H, Okamoto M, et al.:Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. Br J Haematol 123:621-630, 2003
  pubmed

P.378 掲載の参考文献

• i) Niitsu N, Kohri M, Higashihara M, et al.:Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 98:109-112, 2007
  pubmed

P.384 掲載の参考文献

• 1) Lymphoma Study Group of Japanese Pathologists:The world health organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000

• 2) Au WY, Ma SY, Chim CS, et al.:Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme:a single center experience of 10 years. Ann Oncol 16:206-214, 2005

• 3) Arber DA, Weiss LM, Albujar PF, et al.:Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 17:392-399, 1993
  pubmed

• 4) Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, et al.:Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 11:754-761, 1998
  pubmed

• 5) Tien HF, Su IJ, Tang JL, et al.:Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas. Br J Haematol 97:621-625, 1997
  pubmed

• 6) Nakashima Y, Tagawa H, Suzuki R, et al.:Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia:different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 44:247-255, 2005
  pubmed

P.394 掲載の参考文献

• 1) Chan JKC, Quintanilla-Martinez L, Ferry JA, et al.:Extranodal NK/T-cell lymphoma, nasal type. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC, Lyon, 2008, pp285-288

• 2) Oshima K:Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139:532-544, 2007

• 3) Suzuki R:Leukemia and lymphoma of natural killer cells. J Clin Exp Hematopathol 45:51-70, 2005

• 4) 鈴宮淳司, 大島孝一:NK細胞リンパ腫:病因と臨床像. 臨床血液 49:545-552, 2008

• 5) Suzuki R, Yamamoto K, Seto M, et al.:CD7+and CD56+ myeloid/natural killer cell precursor acute leukemia:a distinct hematolymphoid disease entity. Blood 90:2417-2428, 1997
  pubmed

• 6) Suzuki R, Nakamura S, Suzumiya J, et al.:Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor):prognostication and categorization according to anatomic sites of involvement. Cancer 104:1022-1031, 2005
  pubmed

• 7) Hercend T, Schmidt RE:Characteristics and uses of natural killer cells. Immunol Today 9:291-293, 1988
  pubmed

• 8) Farag SS, Caligiuri MA:Human natural killer cell development and biology. Blood Rev 20:123-137, 2006
  pubmed

• 9) Sanchez MJ, Muench MO, Roncarolo MG, et al.:Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 180:569-576, 1994

• 10) Ng CS, Chan JK, Lo ST:Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol 18:1257-1262, 1987
  pubmed

• 11) 大野敏之, 塚田哲也, 川上惠基ほか:Natural killer 細胞由来の鼻腔原発悪性リンパ腫の1例. 臨床血液 31:487-491, 1990

• 12) Suzumiya J, Takeshita M, Kimura N, et al.:Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 83:2255-2260, 1994
  pubmed

• 13) Kaneko T, Fukuda J, Yoshihara T, et al.:Nasal natural killer (NK) cell lymphoma:report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells. Br J Haematol 91:355-361, 1995
  pubmed

• 14) Kawa-Ha K, Ishihara S, Ninomiya T, et al.:CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 84:51-55, 1989
  pubmed

• 15) Harabuchi Y, Yamanaka N, Kataura A, et al.:Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128-130, 1990
  pubmed

• 16) Jaffe ES, Chan JK, Su IJ, et al.:Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg J Pathol 20:103-111, 1996

• 17) The World Health Organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50:696-702, 2000

• 18) Ko YH, Kim CW Park CS, et al.:REAL classification of malignant lymphomas in the Republic of Korea:incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83:806-812, 1998

• 19) Au WY, Weisenburger DD, Intragumtornchai T, et al.:Clinical differences between nasal and extranasal natural killer/T-cell lymphoma:a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood 113:3931-3937, 2009
  pubmed

• 20) Vose J, Armitage J, Weisenburger D, et al.:International peripheral T-cell and naturall killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008

• 21) Kwong YL, Chan AC, Liang RH:Natural killer cell lymphoma/leukemia:pathology and treatment. Hematol Oncol 15:71-79, 1997
  pubmed

• 22) Wong KE Chan JK, Cheung MM, et al.:Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Ann J Clin Pathol 115:266-270, 2001

• 23) Ohshima K, Haraokaa S, Ishihara S, et al.:Analysis of chromosome 6q deletion in EBV-associated NK cell leukaemia/lymphoma. Leuk Lymphoma 43:293-300, 2002
  pubmed

• 24) Nakashima Y, Tagawa H, Suzuki R, et al.:Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia:different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/Tcell lymphoma, nasal type. Genes Chromosomes Cancer 44:247-255, 2005

• 25) Suzumiya J, Ohshima K, Takeshita M, et al.:Nasal lymphomas in Japan:a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. Leuk Lymphoma 35:567-578, 1999
  pubmed

• 26) Liu Q, Ohshima K, Sumie A, et al.:Nasal CD56 positive small round cell tumors. Differential diagnosis of hematological, neurogenic, and myogenic neoplasms. Virchows Arch 438:271-279, 2001
  pubmed

• 27) Kako S, Izutsu K, Ota Y, et al.:FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685-1690, 2007

• 28) Tsukamoto N, Kojima M, Hasegawa M, et al.:The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-pet with 67gallium scintigraphy in the evaluation of lymphoma:relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652-659, 2007

• 29) Miller TP, Dahlberg S, Cassady JR, et al.:Chemotherapy alone compared with chemotherapy plus radiotherapy for localize d intermediate-and high-grade non-Hodgkin's lymphoma. N Engl Med 339:21-26, 1998

• 30) Yamaguchi M, Ogawa S, Nomoto Y, et al.:Treatment outcome of nasal NK-cell lymphoma:A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematopathol 41:93-99, 2001

• 31) Yamaguchi M, Kita K, Miwa H, et al.:Frequent expression of P-glycoprotein/MDRI by nasal T-cell lymphoma cells. Cancer 76:2351-2356, 1995

• 32) Egashira M, Kawamata N, Sugimoto K, et al.:P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93:599-606, 1999
  pubmed

• 33) Isobe K, Uno T, Tamaru J, et al.:Extranodal natural killer/T-cell lymphoma, nasal type:the significance of radiotherapeutic parameters. Cancer 106:609-615, 2006
  pubmed

• 34) Ribrag V, Ell Hajj M, Janot F, et al.:Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 15:1123-1126, 2001
  pubmed

• 35) Li YX, Yao B, Jin J, et al.:Radiotherapy as primary treatment for stage I E and II E nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181-189, 2006

• 36) Yamaguchi M, Oguchi M, Tobinai K, et al.:Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma:results of a phase I portion of JCOG0211-DI. Blood 106:2685, 2005

• 37) Chim CS, Ma Sy, Au WY, et al.:Primary nasal natural killer cell lymphoma:long-term treatment outcome and relationship with the International Prognostic Index. Blood 103:216-221, 2004
  pubmed

• 38) Lee J, Suh C, Park YH, et al.:Extranodal natural killer T-cell lymphoma, nasal-type:aprognostic model from a retrospec-tive multicenter study. J Clin Oncol 24:612-618, 2006

• 39) Aviles A, Neri N, Fernandez R, et al.:Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 20:13-17, 2003
  pubmed

• 40) Yong W, Zheng W Zhang Y, et al.:L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/ NK-cell lymphoma. Int J Hematol 78:163-167, 2003

• 41) Yong W Zheng W Zhu J, et al.:L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 88:647-652, 2009

• 42) Jaccard A, Petit B, Girault S, et al.:L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 20:110-116, 2009

• 43) Yamaguchi M, Suzuki R, Kwong YL, et al.:Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016-1020, 2008
  pubmed

• 44) Kim K, Ryu K, Ko Y, et al.:Effects of nuclear factor-κB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Hematol 131:59-66, 2005

• 45) Lee J, Suh C, Kang HJ, et al.:Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 19:2079-2083, 2008

• 46) Au WY, Lie AK, Liang R, et al.:Autologous stem cell transplantation for nasal NK/T-cell lymphoma:a progress report on its value. Ann Oncol 14:1673-1676, 2003
  pubmed

• 47) Kim HJ, Bang SM, Lee J, et al.:High-dose chemotherapy with autologous stem cell transplantation in extranod al NK/Tcell lymphoma:a retrospective comparison with non-trans-plantation cases. Bone Marrow Transplant 37:819-824, 2006

• 48) Suzuki R, Suzumiya J, Nakamura S, et al.:Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 37:425-431, 2006
  pubmed

• 49) Lee J, Au WY, Park MJ, et al.:Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma:a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 14:1356-1364, 2008
  pubmed

• 50) Makita M, Maeda Y, Takenaka K, et al.:Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions. Int J Hematol 76:94-97, 2002
  pubmed

• 51) Kim TM, Park YH, Lee SY, et al.:Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I E/II E extranodal NK/T-cell lymphoma, nasal type. Blood 106:3785-3790, 2005

• 52) Lin CW, Chen YH, Chuang YC, et al.:CD94 transcripts simply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Btood 102:2623-2631, 2003

• 53) Takahara M, Kishibe K, Bandoh N, et al.:P53, N-and K-Ras, and β-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol 35:86-95, 2004

• 54) Huang WT, Chang KC, Huang GC, et al.:Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica 90:1063-1069, 2005
  pubmed

P.405 掲載の参考文献

• 1) Takatsuki K:Overview of adult T-cell leukemia/lymphoma. Jpn Soc Res 25:97-103, 1985

• 2) Tajima K, Hinuma Y:Epidemiology of HTLV-I/II in Japan and the world. Gann Mono Can Res 39:129-149, 1992

• 3) Watanabe T, Yamaguchi K, Takatsuki K, et al.:Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-I) carriers and adult T cell leukemia patients which can be trans-activated by HTLV-I Tax gene. J Exp Med 172:759-765, 1990

• 4) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia/lymphoma. A report from The Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991

• 5) Takatsuki K, Yamaguchi K, Watanabe T:Adult T-cell leuke-mia and HTLV-I related diseases. Gann Mono Can Res 39:1-15, 1992

• 6) Ohshima K, Suzumiya J, Sato M, et al.:Survival of patients with HTLV-I-associated lymph node lesions. J Pathol 189:539-545, 1999

• 7) Ohshima K, Kikuchi M, Masuda Y, et al.:Human T-cell leuke-mia virus type 1 associated lymphadenitis. Cancer 69:239-248, 1992

• 8) Ohshima K, Suzumiya J, Kato A, et al.:Clonal HTLV-I-infected CD4+lymphocytes and non-clonal non-HTLV-1-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer 72:592-598, 1997

• 9) 城野昌義:皮膚科からみた成人T細胞白血病・リンパ腫. 成人T細胞白血病・リンパ腫 (血液科学シリーズ6), 高月清 編, 西村書店, 1992, pp55-84

• 10) Yamaguchi T, Ohshima K, Karube K, et al.:Clinicopathological features of cutaneous lesions of adult T-cell leukemia/lymphoma. Br J Dermatol 152:76-81, 2005
  pubmed

• 11) Utsunomiya A, Hanada S, Terada A, et al.:Adult T-cell leukemia with leukemia cell infiltration into the gastrointestinal tract. Cancer 61:824-828, 1988
  pubmed

• 12) Akizuki S, Setoguchi M, Nakazato O, et al.:An autopsy case of human T-lymphotropic virus type I-associated myelopathy Hum Pathol 19:988-990, 1988

• 13) Osame M, Usuku K, Izumo S, et al.:HTLV-I associated myeopathy, a new clinical entity. Lancet i:1031-1032, 1986

• 14) 木村郁郎:HABA (HTLV-I関連細気管支肺胞異常症, HTLV-I associated bronchiolo-alveolar disorder). 日本胸部疾患学会雑誌 30:787-795, 1992

• 15) 北市正則, 杉本峯晴, 池田顕彦ほか:HTLV-I関連気道病変. 病理と臨床 20:944-949, 2002

P.415 掲載の参考文献

• 1) Takatsuki K, Matsuoka M, Yamaguchi K:ATL and HTLV-1-related diseases. In:Adult T cell Leukaemia, ed by Takatsuki K, New York, Oxford University Press, 1994, pp 1-27

• 2) Ohshima K, Jaffe ES, Kikuchi M:Adult T-cell leukaemia/lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., Lyon, IARC, 2008, pp281-284

• 3) Karube K, Ohshima K, Tsuchiya T, et al.:Expression of FoxP3, a key molecule in CD4CD25 regulatory T-cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 126:81-84, 2004
  pubmed

• 4) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report f rom the Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991

• 5) Aoki R, Karube K, Sugita Y, et al.:Distribution of malignant lymphoma in Japan:analysis of 2260 cases, 2001-2006. Pathol Int 58:174-182, 2008
  pubmed

• 6) Tajima K:The 4th nationwide study of adult T-cell leukemia/lymphoma (ATL) in Japan:estimates of risk of ATL and its geographical and clinical features. The T-and B-cell Malignancy Study Group. Int/Cancer 45:237-243, 1990

• 7) Hino S:Primary prevention of adult T cell leukemia (ATL) in Nagasaki, Japan by refraining from breast-feeding. In:Two decades of adult T-cell leukemia and HTLV-1 research. Gann Monograph on Cancer Research 50, ed by Sugamura K, Uchiyama T, Matsumoto M, et al., Scientific Society Press, Tokyo, 2003, pp241-25

• 8) Vose J, Armitage J, Weisenburger D, et al.:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
  pubmed

• 9) Itoyama T, Chaganti RS, Yamada Y, et al.:Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma:a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 97:3612-3620, 2001
  pubmed

• 10) Tsukasaki K, Krebs J, Nagai K, et al.:Comparative gen omic hybridization analysis in adult T-cell leukemia/lymphoma:correlation with clinical course. Blood 97:3875-3881, 2001

• 11) Oshiro A, Tagawa H, Ohshima K, et al.:Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 107:4500-4507, 2006
  pubmed

• 12) Major prognostic factors of patients with adult T-cell leukemia-lymphoma:a cooperative study Lymphoma Study Group (1984-1987). Leuk Res 15:81-90, 1991

• 13) 木下研一郎:成人T細胞白血病・リンパ腫 (ATLL) の臨床-血液・検査・病理-. 成人T細胞白血病・リンパ腫, 木下研一郎編, 新興医学出版社, 東京, 2003, pp18-38

• 14) 宇都宮與:ATL の臨床. 臨床血液 47:1502-1513, 2006

• 15) Ohshima K, Suzumiya J, Sato K, et al.:Nodal T-cell lym-phoma in an HTLV-I-endemic area:proviral HTLV-I DNA, histological classification and clinical evaluation. Br J Hae-matol 101:703-711, 1998

• 16) Takeshita M, Akamatsu M, Ohshima K, et al.:CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology 26:539-546, 1995
  pubmed

• 17) Tsukasaki K, Hermine O, Bazarbachi A, et al.:Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma:a proposal from an international consensus meeting. J Clin Oncol 27:453-459, 2009
  pubmed

• 18) Tamura K, Makino S, Araki Y, et al.:Recombinant interferon beta and gamma in the treatment of adult T-cell leukemia. Cancer 59:1059-1062, 1987
  pubmed

• 19) Gill PS, Harrington W Jr, Kaplan MH, et al.:Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332:1744-1748, 1995
  pubmed

• 20) Tobinai K, Watanabe T, Jaffe ES:Human T-cell Leukemia Virus Type I-Associated Adult T-cell Leukemia-Lymphoma. In:Non-Hodgkin's lymphomas, ed by Mauch PM, Armitage JO, Coiffier B, et al., Lippincott Williams & Wilkins, Philadelphia, 2004, pp295-305

• 21) Shimoyama M, Ota K, Kikuchi M, et al.:Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 6:128-141, 1988
  pubmed

• 22) Tsukasaki K, Tobinai K, Shimoyama M, et al.:Deoxyco-formycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 77:164-170, 2003

• 23) Taylor GP, Matsuoka M:Natural history of adult T-cell leukemia/lymphoma and approaches to therapy Oncogene 24:6047-6057, 2005
  pubmed

• 24) Tsukasaki K, Utsunomiya A, Fukuda H, et al.:VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458-5464, 2007

• 25) Yamada Y, Tomonaga M, Fukuda H, et al.:A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma:Japan Clinical Oncology Group Study 9303. Br J Haematol 113:375-382, 2001

• 26) Suzumiya J, Ohshima K, Tamura K, et al.:The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma:analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol 20:715-721, 2009
  pubmed

• 27) Shimoyama M:Chemotherapy of ATL. In:Adult T-cell Leukaemia, ed by Takatsuki K, Oxford University Press, Oxford, 1994, pp221-237

• 28) Ohno N, Tani A, Chen ZS, et al.:Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res 7:3120-3126, 2001
  pubmed

• 29) Ohno N, Tani A, Uozumi K, et al.:Expression of functional lung resistance--related protein predicts poor outcome in adult T-cell leukemia. Blood 98:1160-1165, 2001
  pubmed

• 30) Tsukasaki K, Maeda T, Arimura K, et al.:Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma:a case report and review of the literature. Bone Marrow Transplant 23:87-89, 1999
  pubmed

• 31) Borg A, Yin JA, Johnson PR, et al.:Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Haematol 94:713-715, 1996
  pubmed

• 32) Fukushima T, Miyazaki Y, Honda S, et al.:Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19:829-834, 2005

• 33) Kato K, Kanda Y, Eto T, et al.:Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma:retrospective analysis of data from the Japan Marrow Donor
  pubmed

• 34) Program. Biol Blood Marrow Transplant 13:90-99, 2007 Okamura J, Uike N, Utsunomiya A:Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma. Int J Hematol 86:118-125, 2007

• 35) Momita S, Ikeda S, Amagasaki T, et al.:Survey of anti-human T-cell leukemia virus type I antibody in family members of patients with adult T-cell leukemia. Jpn J Cancer Res 81:884-889, 1990
  pubmed

• 36) Satou Y, Nosaka K, Koya Y, et al.:Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18:1357-1363, 2004
  pubmed

• 37) Watanabe M, Ohsugi T, Shoda M, et al.:Dual target ing of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106:2462-2471, 2005

• 38) Ishitsuka K, Suzumiya J, Aoki M, et al.:Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica 92:719-720, 2007
  pubmed

• 39) Arima N, Mizoguchi H, Shirakawa S, et al.:[Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma]. Gan To Kagaku Ryoho 26:619-629, 1999
  pubmed

• 40) Yoshie O, Fujisawa R, Nakayama T, et al.:Frequent exp ressionof CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99:1505-1511, 2002

• 41) Ishida T, Iida S, Akatsuka Y, et al.:The CC chemokine recep-tor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 10:7529-7539, 2004

• 42) Osborne GE, Pagliuca A, Ho A, et al.:Novel treatment of Sezary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody). Br J Dermatol 155:617-620, 2006

• 43) Kamihira S, Atogami S, Sohda H, et al.:Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 73:2753-2758, 1994
  pubmed

• 44) Yamada Y, Hatta Y, Murata K, et al.:Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 15:1778-1785, 1997
  pubmed

• 45) Kubuki Y, Suzuki M, Sasaki H, et al.:Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma 46:393-399, 2005
  pubmed

• 46) Takasaki Y, Iwanaga M, Tsukasaki K, et al.:Impact of visceralinvolvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res 31:751-757, 2007
  pubmed

P.432 掲載の参考文献

• 1) Matutes E, Brito-Babapulle V, Swansbury J, et al.:Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78:3269-3274, 1991
  pubmed

• 2) Pekarsky Y, Hallas C, Isobe M, et al.:Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci USA 96:2949-2951, 1999

• 3) Pandolfi E Loughran TP Jr, Starkebaum G, et al.:Clinical course and prognosis of the lyrnphoproliferative disease of granular lymphocytes. A multicenter study Cancer 65:341-348, 1990

• 4) Rabbani GR, Phyliky RL, Tefferi A:A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 106:960-966, 1999
  pubmed

• 5) Song SY, Kim WS, Ko YH, et al.:Aggressive natural killer cell leukemia:clinical features and treatment outcome. Haemato-logica 87:1343-1345, 2002

• 6) Nakashima Y, Tagawa H, Suzuki R, et al.:Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia:different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 44:247-255, 2005
  pubmed

• 7) Su IJ, Chen RL, Lin DT, et al.:Epstein-Barr virus (EBV) infects T lymphocytes in childhood EBV-associated hemophagocytic syndrome in Taiwan. Am J Pathol 144:1219-1225, 1994
  pubmed

• 8) Kikuta H, Sakiyama Y, Matsumoto S, et al.:Fatal Epstein-Barr virus-associated hemophagocytic syndrome. Blood 82:3259-3264, 1993
  pubmed

• 9) Kimura H, Hoshino Y, Kanegane H, et al.:Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98:280-286, 2001
  pubmed

• 10) Suzuki K, Ohshima K, Karube K, et al.:Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. Int/Oncol 24:1165-1174, 2004

• 11) Vose J, Armitage J, Weisenburger D, et al.:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
  pubmed

• 12) Wright DH:Enteropathy associated T cell lymphoma. Cancer Surv 30:249-261, 1997
  pubmed

• 13) Howell WM, Leung ST, Jones DB, et al.:HLA-DRB,-DQA, and-DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Hum Immunol 43:29-37, 1995
  pubmed

• 14) Belhadj K, Reyes F Farcet JP, et al.:Hepatosplenic γδT-cell lymphoma is a rare clinicopathologic entity with poor outcome:report on a series of 21 patients. Blood 102:4261-4269, 2003

• 15) Wu H, Wasik MA, Przybylski G, et al.:Hepatosplenic γδT-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients. Am/Clin Pathol 113:487-496, 2000

• 16) Macon WR, Levy NB, Kurtin PJ, et al.:Hepatosplenic αβT-cell lymphomas:a report of 14 cases and comparison with hepatosplenic γδT-cell lymphomas. Am J Surg Pathol 25:285-296, 2001

• 17) Wlodarska I, Martin-Garcia N, Achten R, et al.:Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma:isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 33:243-251, 2002
  pubmed

• 18) Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al.:Non hepatosplenic γδT-cell lymphoma:a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 91:1723-1731, 1998

• 19) Kumar S, Krenacs L, Medeiros J, et al.:Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 29:397-403, 1998
  pubmed

• 20) Willemze R, Jansen PM, Cerroni L, et al.:Subcutaneous panniculitis-like T-cell lymphoma:definition, classification and prognostic factors. An EORTC Cutaneous Lympholna Group study of 83 cases. Blood 111:838-845, 2007

• 21) Toro JR, Liewehr DJ, Pabby N, et al.:γδ-T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101:3407-3412, 2003

• 22) Ralfkiaer E:Immunohistological markers for the diagnosis of cutaneous lymphomas. Semin Diagn Pathol 8:62-72, 1991
  pubmed

• 23) Fierro MT, Comessatti A, Quaglino B et al.:Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sezary syndrome. Dermatology 213:284-292, 2006

• 24) Mao X, Lillington DM, Czepulkowski B, et al.:Molecular cytogenetic characterization of Sezary syndrome. Genes Chromo-somes Cancer 36:250-260, 2003

• 25) de Bruin PC, Beljaards RC, van Heerde P, et al.:Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic Iarge cell lymphoma of T-cell or null cell phenotype. Histopathology 23:127-135, 1993
  pubmed

• 26) Bekkenk MW, Geelen EA, van Voorst Vader PC, et al.:Primary and secondary cutaneous CD30+ lymphoproliferative disorders:a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661, 2000

• 27) Berti E, Tomasini D, Vermeer MH, et al.:Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphoma:a distinct clinicopathologic entity with an aggressive clinical behavior. Am J Pathol 155:483-492, 1999
  pubmed

• 28) Bekkenk MW Vermeer MH, Jansen PM, et al.:Peripheral T-cell lymphomas unspecified presenting in the skin:analysis of prognostic factors in a group of 82 patients. Blood 102:2213-2219, 2003

P.445 掲載の参考文献

• 1) Hodgkin T:On some morbid appearances of the absorbent glands and spleen. Med Chir Soc Tr 17:68-114, 1832

• 2) Wilks S:Cases of enlargement of the lymphatic glands and spleen (or, Hodgkin's disease) with remarks. Guy's Hosp Rep 11:56-67, 1856

• 3) Tamaru J, Hummel M, Zemlin M, et al.:Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 84:708-715, 1994

• 4) Ohno T, Stribley JA, Wu G, et al.:Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl Med 337:459-465, 1997
  pubmed

• 5) Marafioti T, Hummel M, Anagnostopoulos I, et al.:Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. Engl J Med 337:453-458, 1997

• 6) Kanzler H, KUppers R, Hansmann ML, et al.:Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the out-growth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184:1495-1505, 1996

• 7) Anagnostopoulos I, Hansmann ML, Franssila K, et al.:European Task Force on Lymphoma project on lymphocyte predomi-nance Hodgkin disease:histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with anodular growth pattern and abundant lymphocytes. Blood 96:1889-1899, 2000

• 8) Prakash S, Fountaine T, Raffeld M, et al.:IgD positive L & H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 30:585-592, 2006

• 9) Zukerberg LR, Collins AB, Ferry JA, et al.:Coex pression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol 139:475-483, 1991

• 10) Tamaru J, Mikata A, Azuma K, et al.:Reciprocal/dichotomic expression of vimentin and B cell differentiation antigens in Reed-Sternberg's cells. Virchows Arch A Pathol Anat Histopathol 416:213-220, 1990

• 11) Foss HD, Reusch R, Demel G, et al.:Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 94:3108-3113, 1999

• 12) Tamaru J, Tokuhira M, Nittsu N, et al.:Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma. Leuk Lymphoma 48:1127-1138, 2007
  pubmed

• 13) Marafioti T, Hummel M, Foss HD, et al.:Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95:1443-1450, 2000
  pubmed

• 14) Loddenkemper C, Anagnostopoulos I, Hummel M, et al.:Differential Emu enhancer activity and expression of BOB. 1/OBF 1, Oct2, PU. 1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 202:60-69, 2004
  pubmed

• 15) Seitz V, Hummel M, Marafioti T, et al.:Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95:3020-3024, 2000
  pubmed

• 16) Delsol G, Brousset P, Chittal S, et al.:Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease. Am J Pathol 140:247-253, 1992
  pubmed

• 17) MacLennan KA, Bennett MH, Vaughan Hudson B, et al.:Diag-nosis and grading of nodular sclerosing Hodgkin's disease:a study of 2190 patients. Int Rev Exp Pathol 33:27-51, 1992

• 18) von Wasielewski S, Franklin J, Fischer R, et al,:Nodular sclerosing Hodgkin disease:new grading predicts prognosis in intermediate and advanced stages. Blood 101:4063-4069, 2003
  pubmed

• 19) Asano N, Yamamoto K, Tamaru J, et al.:Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders:comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 113:2629-2636, 2009
  pubmed

• 20) Vassallo J, Lamant L, Brugieres L, et al.:ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma:report of 10 cases. Am J Surg Pathol 30:223-229, 2006
  pubmed

• 21) Ohshima K, Suzulniya J, Kato A, et al.:Clonal HTLV-1-infected CD4+T-lymphocytes and non-clonal non-HTLV-1-infected giant cells in incipient ATLL with Hodgkin-like histo-logic features. Int J Cancer 72:592-598, 1997

P.446 掲載の参考文献

• i) Traverse-Glehen A, Pittaluga S, Gaulard P, et al.:Mediastinal gray zone lymphoma:the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg. Pathol 29:1411-1422, 2005

• ii) Garcia JE Mollejo M, Fraga M, et al.:Large B-cell lymphoma with Hodgkin's features. Histopathology 47:101-110, 2005

P.457 掲載の参考文献

• 1) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 2) Mauch PM, Kalish LA, Kadin M, et al.:Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 71:2062-2071, 1993
  pubmed

• 3) Anselmo AP, Proia A, Cartoni C, et al.:Meningeal localization in a patient with Hodgkin's disease. Description of a case and review of the literature. Ann Oncol 7:1071-1075, 1996

• 4) Cervantes E Briones J, Bruguera M, et al.:Hodgkin's disease presenting as a cholestatic febrile illness:incidence and main characteristics in a series of 421 patients. Ann Hematol 72:357-360, 1996

• 5) Tsang P, Cesarman E, Chadburn A et al.:Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol 148:2017-2025, 1996
  pubmed

• 6) Joos S, Otafio-Joos MI, Ziegler S, et al.:Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromo-somal material including 9p and amplification of the REL gene. Blood 87:1571-1578, 1996

• 7) Anderson H, Deakin DP, Wagstaff J, et al.:A randomised study of a adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS I A-II B:a report from the Manchester lymphoma group. Br J Cancer 49:695-702, 1984

• 8) Noordijk EM, Carde P, Dupouy N, et al.:Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma:long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128-3135, 2006
  pubmed

• 9) Engert A, Schiller P, Josting A, et al., German Hodgkin's Lymphoma Study Group:Involved-field radiotherapy is equally effective and less toxic compared with extended-field radio-therapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003

• 10) Meyer RM, Gospodarowicz MK, Connors JM, et al., Eastern Cooperative Oncology Group:Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005

• 11) Noordijk EM, Carde P, Mandard AM, et al.:First results of the EORTC-GELA H9 randomized trials:H9-F trial (comparing 3radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL) (abstr). J Clin Oncol 23(suppl 6):A-6505, 561S, 2005

• 12) Bonadonna G, Bonfante V, Viviani S, et al.:ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease:long-term results. J Clin Oncol 22:2835-2841, 2004
  pubmed

• 13) Eich HT, Staar S, Gossmann A, et al., German Hodgkin Study Group:Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 58:1121-1127, 2004

• 14) Evens AM, Hutchings M, Diehl V:Treatment of Hodgkin lymphoma:he past, present, and future. Nat Clin Pract Oncol 5:43-556, 2008

• 15) Straus DJ, Portlock CS, Qin J, et al:Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinbla tine, and dacarbazine (ABVD) followed by radiation therapy (RT) ersus ABVD alone for stages I, II, and IHA nonbulky Hodgkin disease. Blood 104:3483-3489, 2004

• 16) DeVita VT Jr, Simon RM, Hubbard SM, et al. Curability of dvanced Hodgkin's disease with chemotherapy Long-term follow-up of MOPP-treated patients at the National Cancer nstitute. Ann Intern Med 92:587-595, 1980

• 17) Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP Cancer 6:252-259, 1975
  pubmed

• 18) Caneuos GP, Anderson JR, Propert KJ, et al.:Chemoterapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
  pubmed

• 19) Takenaka T, Mikuni C, Miura A, et al.:Alter ating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, inblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease:multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn Clin Oncol 30:146-152, 2000

• 20) Diehl V, Franklin J, Hasenclever D, et al.:BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective s COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma:interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16:3810-821, 1998

• 21) Engel C, Loeffler M, Schmitz S, et al.:Acute hemato ogic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 11:1105-114, 2000

• 22) Hasenclever D, Diehl V:Aprognostic score for advanced Hodgkin's disease. International Prognostic Factors Projec on dvanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998

• 23) Niitsu N, Okamoto M, Tomita N, et al.:Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma. Leule Lymphoma 47:908-1914, 2006

• 24) Federico M, Luminari S, Iannitto E, et al.:ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma:results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 27:805-811, 2009

• 25) Horning SJ, Hoppe RT, Breslin S, et al.:Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease:mature results of a prospective clinical trial. J Clin Oncol 20:30-637, 2002

• 26) Horning SJ, Williams J, Bartlett NL, et al.:Assessment of thestanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease:Eastern Cooperative Oncology Group pilot study E 1492. J Clin Oncol 18:972-980, 2000

• 27) Hutchings M, Mikhaeel NG, Fields PA, et al.:Prognostic alue of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160-1168, 2005
  pubmed

• 28) Gallamini A, Hutchings M, Rigacci L, et al.:Early interim 2-8F fluoro-2-deoxy-D-glucose positron emission tomography s prognostically superior to international prognostic sc re in dvanced-stage Hodgkin's lymphoma:a report from a jointtalian-Danish study. J Clin Oncol 25:3746-3752, 2007

• 29) Connors JM, Controversy I:Do we need radiotherapy in early odgkin lymphoma? J Ann Oncol 19:iv82, 2008

• 30) Radford J:Limited-stage disease:optimal use of chemotherapy and radiation treatment. Hematology Am Soc Hematol Educ Program:321-325, 2008
  pubmed

• 31) Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al.:Lymphocyte-rich classical Hodgkin's lymphoma:clinical pr sentation and treatment outcome in 100 patients treated within erman Hodgkin's Study Group trials. J Clin Oncol 23:5739-745, 2005

• 32) Niitsu N, Nakamine H, Okamoto M, et al.:A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma. Ann Oncol 19:1941-1946, 2008

P.458 掲載の参考文献

• i) Swerdlow AJ, Higgins CD, Smith P et al.:Myocardial infarction mortality risk after treatment for Hodgkin disease:a collaborative British cohort study. J Natl Cancer Inst 99:206-214, 2007
  pubmed

• ii) Boice JD Jr:An affair of the heart. J Natl Cancer Inst 99:186-187, 2007

P.462 掲載の参考文献

• 1) Kamel OW, van de Rijn M, Weiss LM, et al.:Brief report:reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Eng J Med 328:1317-1321, 1993

• 2) Salloum E, Cooper DL, Howe G, et al.:Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14:1943-1949, 1996
  pubmed

• 3) Wolfe E Michaud K:The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheu-matoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum 56:1433-1439, 2007

• 4) Mackey AC, Green L, Liang LC, et al.:Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44:265-267, 2007
  pubmed

• 5) Hoshida Y, Xu JX, Fujita S, et al.:Lymphoproliferative disorders in rheumatoid arthritis:clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322-331, 2007
  pubmed

• 6) Kamel OW:Iatrogenic lymphoproliferative disorders in non-transplantation settings. Recent Rusults Cancer Res 159:19-26, 2002

• 7) Mariette X, Cazals-Hatem D, Warszawki J, et al.:Lympho as in rheumatoid arthritis patients treated with methotrexate:a 3-year prospective study in France. Blood 99:3909-3915, 2002

• 8) Kamel OW Weiss LM, van de Rijn M, et al.:Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy Am J Surg Pathol 20:1279-1287, 1996
  pubmed

P.468 掲載の参考文献

• 1) World Health Organization Classification of Tumours:Pathology and Genetics of Tumours of Haematopoietic and Lymophoid tissues, ed by Jaffe ES, Hards NL, Stein H, et al., IARC Press, Lyon, 2001

• 2) WHO Classification of Tumours of Haematopoietic and Lymophoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008

• 3) 森茂郎:総論5. 悪性リンパ腫の発症機序. 最新・悪性リンパ腫アトラス, 菊池昌広, 森茂郎編, 文光堂, 東京, 2004, pp49-56

• 4) 森茂郎, 畑安浩, 出雲俊之ほか:E. 免疫不全関連リンパ腫最新・悪性リンパ腫アトラス, 菊池昌広, 森茂郎編, 文光堂, 東京, 2004, pp293-298

• 5) Loren AW, Porter DL, Stadmauer EA, et al.:Post-transplant lymphoproliferative disorder:a review. Bone Marrow Transplant 31:145-155, 2003

• 6) Oyama T, Ichimura K, Suzuki R, et al.:Senile EBV+B-cell lymphoproliferative disorders:a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16-26, 2003
  pubmed

• 7) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009

• 8) Dal Maso L, Franceschi S:Epidemiology of non-Hodgkin lym-phomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 4:110-119, 2003

• 9) Valencia ME:AIDS-related lymphomas--potentially curable in the HAART era. AIIDS Revs 8:108-110, 2006

• 10) Tsai DE, Hardy CL, Tomaszewski JE, et al.:Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder:analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076-1088, 2001
  pubmed

• 11) Mamzer-Bruneel ME Lome C, Molelon E, et al.:Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation:A report of 16 cases obseved in a single center. J Clin Oncol 18:3622-3632, 2000

• 12) Oertel SH, Verschuuren E, Reinke P, et al.:Effect of anti-CD20 antibody Rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5:2901-2906, 2000

• 13) Vaccher E, Spina M, di Gennaro G, et al.:Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 91:155-163, 2001
  pubmed

• 14) Navarro JT, Ribera JM, Oriol A, et al.:Influence of highly active anti-retrovirus therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Hematol 112:909-915, 2001

• 15) Spina M, Saparano JA, Jaeger U, et al.:Rituximab and chemotherapy is highly effective in patients with CD20-positive non Hodgkin's lymphoma and HIV infection. AIDS 17:137-138, 2003

• 16) Kaplan LD, Lee JY, Ambinder RE et al.:Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-ssociated non Hodgkin lymphoma:AIDS-Malignancies Consortium Trial 010. Blood 106:1538-1543, 2005

• 17) Newell ME, Hoy JE Cooper SG, et al.:Human immunodeficiency virus-related primary central nervous system lymphoma:factors influencing survival in 111 patients. Cancer 100:2627-2636, 2004

• 18) xicoy B, Ribera JM, Miralles P, et al.:Results of treatmentwith doxorubicin, bleomycin, vinbrastine and dacarbazine and ighly active antiretroviral therapy in advanced stage, human mmunodeficiency virus-related Hodgkin's lymphoma. Haematologica 92:191-198, 2007

• 19) Spina M, Gabarre J, Rossi G, et al.:Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and IV infection. Blood 100:1984-1988, 2002

P.469 掲載の参考文献

• ・Re A, Cattaneo C, Michieli M, et al.:High-dose therapy and autologous peripheral-blood stem-cell treatment as salvage treatment for HIV-associated lymphoma in patients receiving highly ctive antiretroviral therapy. J Clin Oncol 21:4423-4427, 2003

• ・Taylor AL, Marcus R, Bradley JA:Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56:155-167, 2005
  pubmed

• ・Navarro WH, Kaplan LD:AIDS-related lymphoproliferative disease. Blood 107:13-20, 2006
  pubmed

• ・Mounier N, Spina M, Gisselbrecht C:Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 136:685-698, 2007
  pubmed

• ・Levin AM:Management of AIDS-related lympholna. Curr Opin Oncol 20:522-528, 2008

• ・Wagner-Johnston ND, Ambinder RF:Blood and marrow transplant for lymphoma patients with HIV/AIDS. Curr Opin Oncol 20:201-205, 2008
  pubmed